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Summary  The  value  of  polymers  is  manifested  in  their  vital  use  as  building  blocks  in  mate-
rial and  life  sciences.  Ribonucleic  acid  (RNA)  is  a  polynucleic  acid,  but  its  polymeric  nature
in materials  and  technological  applications  is  often  overlooked  due  to  an  impression  that  RNA
is seemingly  unstable.  Recent  ﬁndings  that  certain  modiﬁcations  can  make  RNA  resistant  to
RNase degradation  while  retaining  its  authentic  folding  property  and  biological  function,  and
the discovery  of  ultra-thermostable  RNA  motifs  have  adequately  addressed  the  concerns  of  RNA
unstability.  RNA  can  serve  as  a  unique  polymeric  material  to  build  varieties  of  nanostructures
including nanoparticles,  polygons,  arrays,  bundles,  membrane,  and  microsponges  that  have
potential  applications  in  biomedical  and  material  sciences.  Since  2005,  more  than  a  thousand
publications  on  RNA  nanostructures  have  been  published  in  diverse  ﬁelds,  indicating  a  remark-
able increase  of  interest  in  the  emerging  ﬁeld  of  RNA  nanotechnology.  In  this  review,  we  aim
to: delineate  the  physical  and  chemical  properties  of  polymers  that  can  be  applied  to  RNA;
introduce  the  unique  properties  of  RNA  as  a  polymer;  review  the  current  methods  for  the  con-
struction of  RNA  nanostructures;
sciences; and,  discuss  the  challe
© 2015  The  Authors.  Published
BY-NC-ND  license  (http://creati
∗ Corresponding author. Tel.: +1 859 218 0128; fax: +1 859 257 1307.
E-mail address: peixuan.guo@uky.edu (P. Guo).
http://dx.doi.org/10.1016/j.nantod.2015.09.003
1748-0132/© 2015 The Authors. Published by Elsevier Ltd. This 
(http://creativecommons.org/licenses/by-nc-nd/4.0/). describe  its  applications  in  material,  biomedical  and  computer
nges  and  future  prospects  in  this  ﬁeld.
 by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
vecommons.org/licenses/by-nc-nd/4.0/).
is an open access article under the CC BY-NC-ND license
6I
P
e
r
h
m
m
w
t
n
t
s
o
a
h
a
A
i
m
t
c
u
W
d
h
a
r
t
i
R
i
p
a
p
d
t
d
i
n
P
i
T
m
e
c
p
m
p
o
e
b
b
a
r
e
c
e
d
a
o
i
W
n
(
a
o
a
c
b
a
a
a
m
s
p
a
t
t
o
b
s
s
m
d
v
w
o
t
d
m
s
i
p
c
(
(
t
ﬂ
o
c
h
I
s
b
m
w
R
m
a32  
ntroduction
olymers  have  been  extensively  used  by  humans  since  the
arliest  recorded  history.  Tree  saps,  tar  and  plant  ﬁbers,  all
epresent  the  earliest  natural  polymeric  materials  used  by
umans  [1].
Since  the  1950s,  through  continued  synthesis  and
anufacturing  improvements,  synthetic  polymers  have  dra-
atically  improved  in  quality  and  strength  to  the  point
here  they,  in  many  cases,  can  have  mechanical  properties
hat  better  match  desired  use,  as  compared  to  alternative
atural  counterparts.  Synthetic  polymers  have  the  manufac-
uring  advantages  of  rapid  production  rates  and  synthetic
implicity.  However,  owing  to  the  inherently  random  nature
f  most  polymerization  mechanisms,  chain  polydispersity
nd  controlled  shaping  remain  two  of  the  key  limiting
urdles  that  have  led  to  increased  variable  performance
nd  overall  reduced  control  of  the  ﬁnal  properties  [2—4].
s  such,  there  has  been  much  effort  towards  develop-
ng  synthetic  building  blocks  and  schemes  that  can  create
onodisperse  polymer  systems  [5—7].  These,  however,  are
ypically  very  expensive,  time  consuming  and  difﬁcult  to
ontrol.
As  a  result  of  these  developments,  we  are  at  another
nique  turning  point  in  the  evolution  and  design  of  polymers.
e  once  again  turn  towards  nature  as  our  inspiration  for  the
evelopment  of  advanced  biomaterials.  By  applying  what  we
ave  learned  about  the  complexity  and  versatility  of  nucleic
cid  structures,  it  is  now  possible  to  create  materials  with
evolutionary  properties  previously  considered  unattainable
hrough  synthetic  strategies.  Recent  advances  in  RNA  chem-
stry,  RNA  biology  and  RNA  nanotechnology  have  shown  that
NA  as  a  biopolymer  not  only  shares  the  common  character-
stics  of  other  polymers,  but  also  possesses  a  range  of  unique
roperties  advantageous  for  applications  in  nanotechnology
s  well  as  biomedical  and  material  sciences  [8—14].
In  this  review,  we  will  (1)  delineate  the  physiochemical
roperties  of  polymers  that  can  be  applied  to  RNA,  (2)  intro-
uce  the  unique  properties  of  RNA  as  a  polymer,  (3)  review
he  current  methods  for  constructing  RNA  nanostructures  for
iverse  applications,  and  (4)  discuss  the  future  prospects
ncluding  challenges,  solutions  and  new  directions  of  this
ascent  ﬁeld.
hysical and chemical properties of polymers
n relationship to RNA nanotechnology
he  word  (poly)-(mer)  means  (many)-(parts)  and  refers  to
acromolecules  consisting  of  a  large  number  of  repeating
lementary  units  covalently  joined  together.  These  ‘mers’
ontrol  the  inter-chain  interactions,  and  dictate  the  ﬁnal
olymer  characteristics.  Given  the  large  variations  in  poly-
er  morphologies,  multiple  ways  are  used  to  describe
olymer  structure.  Polymers  can  be  formed  from  one  type
f  monomer  (homopolymers)  or  of  various  monomers  (het-
ropolymers).  Heteropolymers  can  be  further  described
y  the  arrangement  of  the  monomers  along  the  back-
one,  including  alternating,  random,  and  block  formations
nd  also  adopt  more  elaborate  structures,  including  star,
ing,  branched,  dendrimeric,  crosslinked,  ladder,  and  oth-
rs  [15—23].  These  large  arrays  of  potential  structures  and
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hemical  diversity  offer  a  rich  repertoire  of  available  prop-
rties  from  which  one  can  custom-design  a  polymer  for  a
esired  application.
Biological  macromolecules,  as  natural  building  blocks,
re  critical  for  the  functioning  of  living  organisms.  RNA  is
ne  of  the  ﬁve  most  important  biological  macromolecules
n  addition  to  DNA,  proteins,  lipids  and  carbohydrates.
ith  some  aspects  similar  to  DNA,  RNA,  composed  of  four
ucleotides  including  adenosine  (A),  cytosine  (C),  guanosine
G)  and  uridine  (U),  is  special  in  its  homogeneity.  RNA  is
 homopolymer  of  nucleotide,  but  is  also  a  heteropolymer
f  A,  U,  G,  and  C.  Each  nucleotide  contains  a  ribose  sugar,
 nucleobase,  and  a  phosphate  group.  The  nucleotides  are
ovalently  linked  together  through  3′ →  5′ phosphodiester
onds  between  adjacent  ribose  units,  giving  the  direction-
lity  to  the  sugar-phosphate  backbone  that  deﬁnes  RNA  as
 polynucleic  acid.  The  phosphate  moieties  in  the  backbone
re  negatively  charged,  making  RNA  a polyanionic  macro-
olecule  at  physiological  pH.  RNA  molecules  are  typically
ingle-stranded;  however,  Watson-Crick  (canonical)  base-
air  interactions  (A:U  and  G:C),  wobble  base  pairing  (such
s  G:U)  [24]  or  other  non-canonical  base  pairing  such  as
welve  basic  geometric  families  of  edge-to-edge  interac-
ion  (Watson-Crick,  Hoogsteen/CH  or  sugar  edge)  with  the
rientation  of  glycosidic  bonds  relative  to  the  hydrogen
onds  (cis  or  trans)  [25—28],  all  together  give  rise  to  various
tructural  conformations  exhibiting  loops,  hairpins,  bulges,
tems,  pseudoknots,  junctions,  etc.,  which  are  essential  ele-
ents  to  guide  and  drive  RNA  molecules  to  assemble  into
esired  structures  [12,29—31].
On  the  contrary,  synthetic  polymers  are  usually  formed
ia  polymerization  reaction,  a  chemical  process  through
hich  many  monomers  form  covalent  bonds  between  each
ther  and  ﬁnally  form  a  long  chain  or  network,  imparting
hem  with  their  desired  structural  properties.
Generally,  the  properties  of  polymers  are  strongly
ependent  on  their  monomer  chemistry.  Moreover,  the
olecular  weight  and  2D  structure  (e.g.,  linear  chain-
haped  structure  or  branch-shaped  structure)  also  play
mportant  roles  in  determining  the  characteristics  and
roperties  of  a  speciﬁc  polymer.  Important  properties  of
hemical  polymers  include  [32]:  (1)  rheological  properties,
2)  solubility,  (3)  volumetric  and  viscometric  properties,
4)  stress-strain  relationships,  (5)  electrical  properties,  (6)
hermal  properties,  (7)  optical  properties,  (8)  stiffness,  (9)
ex  life,  (10)  hardness,  (11)  chemical  resistance,  etc.  Vari-
us  physical  or  chemical  tests  can  be  readily  performed  to
haracterize  these  properties  for  RNA  polymers.
Traditional  synthetic  polymers  are  heterogeneous  and
ave  typical  polydispersity  index  greater  than  1  [33,34].
n  contrast,  RNA  is  synthesized  by  either  in  vitro  tran-
cription  or  solid  phase  chemistry.  Both  approaches  are
ased  on  stepwise  reactions  and  will  generate  RNA  poly-
ers  with  deﬁned  sequences,  structures,  and  molecular
eights.  This  leads  to  a  polydispersity  index  of  1  of  a  speciﬁc
NA.  Structurally,  the  average  molecular  weight  deter-
ines  the  mechanical  property  of  the  polymer.  However,
s  polydispersity  increases,  the  increased  lower  molecu-
ar  weight  chains  can  act  as  a  lubricating/solvating  system,
educing  its  mechanical  strength  and  integrity.  As  increases
n  temperature  result  in  increased  molecular  motion,
hese  weak  associations  begin  to  destabilize  and  reduce
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mechanical  integrity.  Such  polymers  are  classically  referred
to  as  thermoplastics  [35],  as  their  mechanical  strength
weakens  with  increased  temperature.  However,  this  prop-
erty  also  means  they  can  be  intentionally  deformed  at  higher
temperatures  and  then  regain  their  structural  properties
once  cooled.  Thermodynamically,  RNA  molecule  is  relatively
more  stable  at  lower  temperature  and  intends  to  dissoci-
ate  or  misfold  at  higher  temperatures.  Thus,  RNA  displays
the  typical  thermoplasticity  of  polymers.  Boiling-resistant
RNA  has  been  discovered  and  constructed  [36],  suggesting  a
potential  application  of  RNA  in  molding  technology.
Chemical  polymers  have  a  wide  range  of  applications
in  biomedical  and  material  sciences.  Speciﬁc  applications
include,  but  not  limited  to  [1,37—50]:  (1)  sutures  for  surgery,
(2)  dental  devices,  (3)  orthopedic  ﬁxation  devices,  (4)  scaf-
folds  for  tissue  engineering,  (5)  drug  formulation  (e.g.,
controlled  release  of  drugs,  excipients  for  drug  stabiliza-
tion  or  solubilization),  (6)  biodegradable  vascular  stents,  (7)
biodegradable  soft  tissue  anchors,  (8)  implantable  biomed-
ical  devices,  (9)  ﬂexible  transparent  displays,  (10)  ﬁeld
effect  transistors,  (11)  solar  cell  panels,  (12)  printing  elec-
tronic  circuits,  (13)  organic  light-emitting  diodes,  (14)
supercapacitors,  etc.  Usually,  an  ideal  chemical  polymer
for  biomedical  and  industrial  applications  should  exhibit
the  majority  of  the  following  properties:  (1)  non-toxic,  (2)
no  or  low  immunogenicity  (if  applicable,  for  in  vivo  use),
(3)  biodegradable  and  metabolizable,  (4)  mechanical  fea-
tures  that  ﬁt  the  needs  of  the  speciﬁc  application,  (5)  easily
sterilizable,  (6)  processability,  (7)  scalability,  (8)  electrical
conductivity,  and  (9)  thermostabilty.  RNA  as  a  polymer  favor-
ably  displays  many  of  these  properties,  as  described  below.
Unique properties of RNA as a polymer to
build nanostructures
The  2′-hydroxyl  group  makes  RNA  dramatically
different  from  DNA
The  characteristic  of  RNA  that  deﬁnes  and  differentiates  it
from  DNA  is  the  2′-hydroxyl  on  each  ribose  sugar  of  the  back-
bone.  The  2′-OH  group  offers  RNA  a  special  property,  which
can  be  either  an  advantage  or  a  disadvantage.  From  a  struc-
tural  point  of  view,  the  advantage  of  this  additional  hydroxyl
group  is  that  it  locks  the  ribose  sugar  into  a  3′-endo  chair
conformation.  As  a  result,  it  is  structurally  favorable  for  the
RNA  double  helix  to  adopt  the  A-form  which  is  ∼20%  shorter
and  wider  rather  than  the  B-form  that  is  typically  present  in
the  DNA  double  helix.  Moreover,  the  2′-OH  group  in  RNA  is
chemically  active  and  is  able  to  initiate  a  nucleophilic  attack
on  the  adjacent  3′ phosphodiester  bond  in  an  SN2  reaction.
This  cleaves  the  RNA  sugar-phosphate  backbone  and  this
chemical  mechanism  underlies  the  basis  of  catalytic  self-
cleavage  observed  in  ribozymes  [51].  The  disadvantage  is
that  the  2′-OH  group  makes  the  RNA  susceptible  to  nuclease
digestion  since  many  RNases  recognize  the  structure  of  RNAs
including  the  2′-OH  group  as  speciﬁc  binding  sites.  However,
such  enzymatic  instability  has  been  overcome  by  applying
chemical  modiﬁcation  of  the  2′-OH  group  (see  the  sections
Enzymatic  stability  of  RNA  and  Methodology  II:  Chemical
modiﬁcation  of  RNA).
a
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hermodynamic  stability  of  RNA
rom  a  thermodynamic  point  of  view,  the  stability  of
he  double  helix  of  RNA  can  be  evaluated  by  measur-
ng  the  Gibbs  free  energy  (G0)  required  for  double
elix  formation,  or  conversely,  double  helix  unwinding
G0 =  −G0helix formation =  G0helix unwinding).  Remarkably,  the
NA  double  helix  is  more  thermodynamically  stable  than  the
NA  double  helix  considering  G0 for  RNA  double  helix  for-
ation  is,  on  the  average,  −3.6  to  −8.5  kJ/mol  per  base
air  stacked  and  G0 for  DNA  double  helix  formation  is
1.4  kJ/mol  per  base  pair  stacked  [52]. Moreover,  the  pres-
nce  of  special  motifs  such  as  bends,  stacks,  junctions  and
oops  in  the  tertiary  structure  of  RNA  may  also  further
mprove  its  stability  [8].  In  addition,  various  proteins,  such
s  RNA  chaperone  proteins,  and  metal  ions,  such  as  Mg2+
ay  also  interact  or  coordinate  with  RNA  and  signiﬁcantly
ontribute  to  the  stability  of  RNA  [53,54].
nzymatic  stability  of  RNA
n  biological  systems,  the  instability  of  RNA  is  mainly  the
esult  of  enzymatic  degradation  by  ribonucleases  (RNases).
he  presence  of  RNases  in  living  organisms  is  universal,
uggesting  that  RNase-mediated  RNA  degradation  is  a  vital
rocess  for  normal  biological  function.  Several  important
oles  of  RNases  have  been  revealed,  including  degrading  sur-
lus  cellular  RNA  [55,56], editing  messenger  RNA,  processing
icroRNA  and  other  non-coding  RNA  during  their  maturation
57,58],  defending  against  the  invasion  of  viral  RNA  [59],
nd  providing  crucial  machinery  for  RNA  interference  (RNAi)
60,61].  RNases  can  be  divided  into  two  major  categories:  (1)
ndo-ribonucleases  that  cleave  phosphodiester  bonds  within
he  RNA  backbone  [62].  Examples  include  RNase  A,  RNase  H,
Nase  I,  RNase  III,  RNase  L,  RNase  P,  RNase  PhyM,  RNase  T1,
Nase  T2,  RNase  U2,  RNase  V,  etc.;  (2)  exo-ribonucleases
hat  cleave  phosphodiester  bonds  at  either  the  5′ or  the  3′
nd  of  an  RNA  chain  [63].  Examples  include  polynucleotide
hosphorylase  (PNPase),  RNase  PH,  RNase  II,  RNase  R,  RNase
,  RNase  T,  oligoribonuclease,  exoribonuclease  I,  exoribonu-
lease  II,  etc.  RNA  is  indeed  very  sensitive  to  degradation  by
Nases,  which  confers  a  very  short  half-life  and  thus  a  poor
harmacokinetic  proﬁle  to  most  RNA  molecules.  This  degra-
ation  limits  the  in  vivo  application  of  RNA  molecules  as
herapeutics.  However,  chemical  modiﬁcations  of  RNA  can
vercome  this  shortcoming.  For  example,  the  substitution
f  the  2′ hydroxyl  group  with  a Fluorine  (2′-F),  O-methyl
2′-O-Me)  or  Amine  (2′-NH2)  dramatically  increases  the  sta-
ility  of  RNA  in  vivo  by  preventing  degradation  by  RNases
64—66]. Recent  studies  also  showed  that  the  stability  of
iRNA  in  serum  is  also  highly  depended  on  the  speciﬁc  RNA
equences  and  the  degradation  of  both  short  and  long  RNA
uplexes  mostly  occurred  at  UA/UA  or  CA/UG  sites  [67].
Synthetic  polymers  always  show  good  stability  against
arious  enzymes.  However,  biodegradable  polymers  that  can
e  degraded  by  enzymes  such  as  proteases,  oxidoreduc-
ases  and  phospholipases  are  more  beneﬁcial  for  therapeutic
pplications  [68].  The  nanocarriers  composed  of  enzyme
ensitive  polymers  can  control  the  site  of  cellular  uptake
f  carriers  and  drug  release  to  improve  the  drug  efﬁcacy
69—71]. Synthetic  polymers  can  also  be  designed  to  be
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on-degradable  or  degradable  under  certain  physiological
onditions.  For  example,  Poly(lactic-co-glycolic  acid)  (PLGA)
which  is  generally  regarded  as  safe)  is  approved  by  FDA,  as
t  can  be  degraded  in  the  body  by  hydrolysis  and  has  now
een  widely  used  to  fabricate  nanoparticles  for  drug  deliv-
ry.  Poly  (beta-amino  ester)  is  another  class  of  degradable
iomaterial  developed  by  Langer  group  [72],  which  can  bind
egatively-charged  RNA  or  DNA  and  facilitate  gene  trans-
ections.  Although  the  biodegradable  polymers  are  highly
ttractive  for  drug  delivery  purposes,  their  degradation
ate  is  very  hard  to  control  and  the  pharmacokinetics  and
iodistribution  proﬁles  of  the  nanocarriers  can  be  elusive.
ynthetic  polymers  usually  are  composed  of  repeated  same
ubunit,  while  RNA  is  the  repetition  of  four  subunits  A,  U,  G
nd  C  in  a  speciﬁc  sequence  order.  Therefore,  RNA  polymers
ight  be  advantageous  concerning  controllable  biodegrad-
bility  [73,74]  simply  by  tuning  the  ratio  and  location  of
′-modiﬁed  nucleotides  in  the  RNA  sequence.
he  versatile  and  plastic  properties  of  RNA
he  versatility  of  RNA  is  highly  evident  given  the  diversity
f  structural  repertoires  available  in  nature,  which  include
imple  structures  such  as  helical  stems  and  single  stranded
airpin  loops  to  more  complicated  structures  such  as  multi-
ay  junctions  and  pseudoknots  [75—84].  Persistence  length
s  a  basic  mechanical  property  used  in  polymer  science  to
easure  the  ﬂexibility  and  stiffness  of  a  polymer.  If  a  poly-
er  is  shorter  than  the  persistence  length,  the  molecule  will
asically  be  a  rigid  rod.  From  a  mechanical  perspective,  the
ersistence  length  of  dsRNA  (62—63  nm)  is  slightly  longer
han  dsDNA  (45—50  nm)  in  an  aqueous  solution  [85,86]. The
tretch  modulus  of  short  dsRNA  (<150  bp)  is  ∼100  pN,  which
s  3  times  lower  than  dsDNA  of  similar  length,  is  based  on  AFM
nd  tweezer  studies  [87].  Interestingly,  RNA  was  observed  to
horten  upon  twisting  with  two-orders  of  magnitude  slower
imescale  compared  to  DNA,  which  in  contrast  lengthened
ith  a  faster  timescale.  More  recently,  single  molecule  force
pectroscopy  were  used  to  study  ∼10  nm  long  dsDNA  con-
aining  ribonucleoside  monophosphates  (rNMPs)  located  at
peciﬁc  positions  within  the  DNA  strands  [88].  The  results
emonstrated  that  the  perturbation  of  stiffness  and  the
lastic  properties  by  rG  intrusions  is  location  and  sequence
ependent,  and  can  either  soften  or  stiffen  the  DNA  com-
lex.  MD  simulations  indicated  that  the  perturbations  are
rom  local  structural  distortions  arising  from  hydrogen  bond-
ng  between  the  OH  group  of  rG  and  electronegative  sites  of
ither  the  phosphate  backbone  or  vicinal  base.  However,
any  factors  such  as  sequence,  local  structural  environ-
ent,  and  metal  ion  concentrations  [89,90]  can  signiﬁcantly
nﬂuence  RNA  versatility,  stiffness  and  plasticity  at  the
olecular  level  [91].  The  balance  of  the  ion-mediated  elec-
rostatic  force  and  the  non-electrostatic  (chemical)  forces
etermine  the  equilibrium  structure  of  the  RNA.  It  is  com-
on  to  ﬁnd  that  one  RNA  molecule  can  exist  in  more  than
ne  conformation,  and  one  kind  of  RNA  molecule  can  dis-
lay  multiple  bands  in  native  gel  electrophoresis  due  to  the
edistribution  of  modular  motif  and  local  thermal  energy.
he  versatile  and  plastic  properties  of  RNA  as  polymer  have
een  applied  to  the  construction  of  RNA  polygons  by  stretch-
ng  the  internal  angle  of  the  three-way  junction  (3WJ)  of
n
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hi29  DNA  packaging  motor  from  60◦ to  90◦ to  108◦ to  transit
rom  triangle,  square,  and  pentagon  structures,  respectively
92].
NA  can  form  complex  3D  structures  in  nanoscale
hile  most  biologically  active  DNAs  are  double-stranded,  in
ontrast,  most  RNAs  in  living  organisms  are  single-stranded.
owever,  RNA  molecules  contain  self-complementary
equences  which  facilitate  the  self-folding  of  these  RNAs.
n  addition  to  Watson-Crick  base  paring,  non-Watson—Crick
ase  pairs  and  coaxial  stacking  of  helices  also  play  important
oles  in  promoting  RNAs  folding  into  complex  3D  structures
12,53].  This  remarkable  folding  capability  not  only  provides
he  structural  basis  for  the  diverse  biochemical  functions  of
ifferent  RNA  molecules,  but  also  provides  huge  opportuni-
ies  for  designing  novel  RNA  nanostructures.  For  example,
he  subdomain  IIa-1  RNA  of  the  IRES  from  HCV  has  a  unique
0◦ bend  L-shaped  structure.  Molecular  modeling  using  this
-shaped  motif  showed  that  a  square  shaped  nanoparti-
le  can  be  formed  with  four  repeating  L-shaped  motifs,  as
eriﬁed  by  gel  shift  assay  and  FRET  assay  [93]  (Fig.  1I).
oreover,  it  has  been  found  that  proteins,  small  molecule
igands  as  well  as  monovalent  and/or  divalent  metal  ions
re  also  important  mediators  of  RNA  folding,  which  could
dd  another  layer  of  complexity  to  the  assembly  of  RNA
anostructures  [53].
oolkits and methodologies for the
onstruction of RNA nanostructures
he  diverse  function  of  RNA  molecules  in  cells  such  as
ibozymes,  riboswitches,  microRNAs,  long  non-coding  RNAs
nd  aptamers  had  attracted  increasing  attention  in  the  sci-
ntiﬁc  community.  All  these  properties  of  RNA  originated
rom  nature  that  RNA  can  adapt  different  structures  and
patial  conformations.  The  laws  of  how  nature  manipulates
NA  structures  can  also  be  explored  to  construct  artiﬁcial
NA  nanostructures.  Besides  the  template-guided  folding  of
NA  nanostructures  that  is  similar  to  the  tactics  in  DNA  nano-
echnology,  self-assembly  of  RNA  building  blocks  is  another
eading  approach  for  bottom-up  RNA  nanotechnology.  A
ide  variety  of  RNA  nanostructures  have  been  success-
ully  constructed  based  on  different  assembly  principles  and
pproaches  (Fig.  1).  In  this  section,  we  will  review  several
oolkits  and  methodologies  that  have  shown  great  success
or  constructing  multifunctional  RNA  nanostructures.
oolkit  I:  Hand-in-hand  interactions  involving  RNA
oops
aking  the  construction  of  a  wooden  table  as  an  analogy,
xternal  dowels  are  used  to  link  variety  of  wood  blocks  into
 structure.  One  of  the  unique  properties  of  RNA  is  its  folding
nto  loops  and  hairpin  structures.  RNA  loops  can  serve  as
nter-RNA  mounting  dovetails,  thus  external  dowels  are  not
ecessary  for  self-assembly  into  unique  structure.
The  packaging  RNA  (pRNA)  in  phi29  DNA  packaging  motor
94—102]  forms  a  hexameric  ring  structure  through  inter-
ocking  of  two  looped  regions  in  each  pRNA  molecule,  named
RNA  as  a  stable  polymer  635
Figure  1  Design  and  construction  of  RNA  nanostructures.  (A)  Phi  29  DNA  packaging  motor  pRNA  hexamer  [110].  Reprinted  with
permission from  Ref.  [110].  Copyright  1998  Elsevier.  (B)  pRNA  dimer  and  trimer  [106].  Adapted  with  permission  from  Ref.  [106].
Copyright 2003  American  Scientiﬁc  Publishers.  (C)  pRNA  arrays  [112].  Reprinted  with  permission  from  Ref.  [112].  Copyright  2004
American Chemical  Society.  (D)  RNA  tecto  squares  [116].  Reprinted  with  permission  from  Ref.  [104].  Copyright  2004  The  American
Association for  the  Advancement  of  Science.  (E)  The  RNA  nanoring  [114].  Reprinted  with  permission  from  Ref.  [114].  Copyright  2007
American Chemical  Society.  (F)  The  tRNA-based  polyhedron  [118].  Reprinted  with  permission  from  Ref.  [118].  Copyright  2010  Nature
Publishing Group.  (G)  Cubic  RNA-based  scaffolds  designed  in  silico  [144].  Reprinted  with  permission  from  Ref.  [144].  Copyright  2010
Nature Publishing  Group.  (H)  Triangular  RNA—protein  complex  [127].  Reprinted  with  permission  from  Ref.  [127].  Copyright  2011
Nature Publishing  Group.  (I)  The  self-assembling  RNA  square  [93].  Reprinted  with  permission  from  Ref.  [93].  Copyright  2011The
National Academy  of  Sciences  of  the  United  States  of  America.  (J)  RNA  microsponges  for  siRNA  delivery  [147].  Reprinted  with
permission from  Ref.  [147].  Copyright  2012  Nature  Publishing  Group.  (K)  pRNA  nanoparticles  fabricated  via  hand-in-hand  and  foot-
to-foot tool  kits  [113].  Reprinted  with  permission  from  Ref.  [113].  Copyright  2013  RNA  Society.  (L)  pRNA  nanoparticles  fabricated
via branch  extension  tool  kit  [113].  Reprinted  with  permission  from  Ref.  [113].  Copyright  2013  RNA  Society.  (M)  Single  stranded
RNA origami  [136].  Reprinted  with  permission  from  Ref.  [136].  Copyright  2014  The  American  Association  for  the  Advancement  of
Science. (N)  Boiling-resistant  RNA  triangles  and  the  array  based  on  RNA  triangles  [36].  Reprinted  with  permission  from  Ref.  [36].
Copyright 2014  American  Chemical  Society.  (O)  The  self-assembled  RNA  membrane  [152].  Reprinted  with  permission  from  Ref.  [152].
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the  right-  and  left-hand  loops  (Fig.  1A).  The  left-hand  and
right-hand  were  brought  together  from  interlocking  inter-
action  among  four  nucleotide  sequences  in  the  loops.  Single
pRNA  molecule  with  self-complimentary  sequences  in  the
loops  can  be  used  to  construct  homodimer  nanoparticles,
or  several  pRNAs  with  the  right-hand  loop  matching  the
sequence  of  the  left-hand  loop  in  another  pRNA  can  be  used
to  construct  heterodimer  nanoparticles.  Through  the  inter-
locking  loop  interactions  between  different  pRNA,  dimer,
trimer,  and  hexamer  RNA  nanoparticles  have  been  created
[103—112].  The  interlocking  loop  sequences  were  further
extended  to  increase  the  thermodynamic  stability  of  gen-
erated  RNA  nanoparticles  [113].  A  toolkit  with  a  set  of
hand-in-hand  loop  sequences  has  been  designed  and  tested
v
c
a
dbe  [139].  Reprinted  with  permission  from  Ref.  [139]. Copyright
or  constructing  stable  RNA  polygonal  nanoparticles.  Loop
xtended  RNA  pairs  with  conﬁrmed  dimer  formation  capa-
ility  were  used  as  building  blocks  for  higher  order  RNA
ligomer  nanoparticles  (Fig.  1B).  Using  a  reengineered  loop
xtended  pRNA  toolkit,  pRNA  dimer,  trimer,  tetramer,  pen-
amer,  hexamer,  and  heptamer  were  constructed  with  highly
fﬁcient  self-assembly,  as  shown  by  gel  shift  assays  and  AFM
maging  [113].
Other  loop—loop  interactions  have  also  been  reported
o  build  various  RNA  nanostructures.  For  example,  nonco-
alent  loop—loop  contacts  based  on  RNAI/IIi  kissing-loop
omplex  have  been  used  to  build  RNA  nanorings  which
re  thermostable,  ribonuclease  resistant  and  capable  of
elivering  RNA  interference  modules  [85,114,115]  (Fig.  1E).
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oreover,  RNA  kiss-loops  were  also  used  to  build  square-
haped  tetrameric  RNA  nanoparticles  and  three-dimensional
olyhedrons  based  on  rationally  designed  RNAs  [116—118]
Fig.  1D and  F).  In  addition,  micrometer-scale  RNA  ﬁlaments
ave  also  been  constructed  by  the  rational  design  of  tectoR-
As  incorporating  4-way  junction  (4WJ)  motifs,  hairpin  loops
nd  their  cognate  loop—receptors  [119,120].
oolkit  II:  Foot-to-foot  interactions  involving
alindrome  sequence  and  sticky  ends
RNA  nanoparticles  can  also  be  constructed  through  the  foot
o  foot  interaction  between  pRNA  monomers.  While  hand-in-
and  interaction  involve  ‘‘left’’  and  ‘‘right’’  hand  and  the
nteraction  is  ‘‘multiple’’  and  ‘‘inter’’  heterosexual,  foot-
o-foot  interaction  includes  only  one  foot  that  is  the  one
nique  palindrome  sequence  by  self-homosexual  interaction
f  the  identical  RNA  molecule.  The  foot  domain  is  located  in
he  helical  5′/3′ open  region  of  pRNA.  Extending  this  region
ith  helical  sequences  does  not  compromise  the  entire  pRNA
olecule  folding.  A  palindrome  sequence  reads  the  same
hether  from  5′ →  3′ direction  on  one  strand  or  from  5′ →  3′
irection  on  the  complementary  strand.  Extending  the  3′end
f  pRNA  monomer  with  a  palindrome  sequence  can  serve
s  a  sticky  end  for  linking  two  pRNA  monomers,  and  is
enoted  as  a  foot-to-foot  interaction  [112].  The  foot-to-foot
nteraction  by  palindrome  sequences  can  also  be  utilized  to
ridge  RNA  nanostructures,  motifs,  or  scaffolds  for  construc-
ing  RNA  hexamers,  octamers,  decamers,  and  dodecamers
Fig.  1K).  A  pRNA  array  was  constructed  by  combining
and  in  hand-loop-interactions  and  foot-to-foot  palindrome
equence  interactions  [112]  (Fig.  1C).  Recently,  strategies
nvolving  both  loop—loop  interaction  and  sticky-end  cohe-
ion  were  also  reported  to  assemble  three-dimensional  and
tructurally  well-deﬁned  RNA  nanoprisms  by  re-engineering
RNA  [121].
oolkit  III:  Grafts  of  motifs  from  naturally-occurring
NA  molecules
ynthetic  RNA  nanoarchitectures  can  be  designed  with  the
nown  naturally-occurring  three-dimensional  RNA  motifs.
articularly,  some  RNA  motifs  in  nature  exhibit  extraordi-
ary  stability,  for  example,  phi29  motor  pRNA  [54,110,122],
RNA  [118],  5S  RNA[123],  and  others  [115].  These  motifs
ave  been  used  to  create  synthetic  RNA  nanostructures
36,93,118,124,125].  The  central  domain  of  the  pRNA
olecule  contains  a  three  way  junction  (3WJ)  core  struc-
ure  [54].  This  3WJ  can  be  assembled  from  three  individual
NA  fragments  with  high  efﬁciency  in  the  absence  of  metal
ons  [123].  The  3WJ  motif  itself  creates  a  branched  structure
hat  allows  for  constructing  multifunctional  RNA  nanoparti-
les  with  different  functional  moieties  at  each  end  of  the
ranches.  RNA  nanoparticles  can  also  be  designed  and  fab-
icated  via  branch  extension  tool  kit  [113]  based  on  the  3WJ
otif  (Fig.  1L).  3WJ  core  retained  its  original  folding  and  the
onjugated  RNA  module  on  the  branches  can  fold  into  their
uthentic  structure  and  remain  functional  [123,126]. For
xample,  after  incorporated  into  3WJ  motif,  HBV  ribozyme
etain  its  capacity  to  cleave  its  RNA  substrate  and  generate
maller  cleavage  products,  and  MG  binding  aptamer  was  also
a
e
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ble  to  bind  MG  to  emit  ﬂuorescence  as  shown  in  the  ﬂuores-
ent  spectra  (Fig.  2A  and  B).  This  property  makes  pRNA  3WJ
tructure  an  extraordinary  nanocarrier  for  targeted  gene
elivery  [123].  Moreover,  an  X-shaped  motif  from  the  cen-
ral  domain  of  the  pRNA  was  discovered  through  extending
he  right-hand  loop  with  a double-stranded  sequence  [73].
he  X-shaped  pRNA  motif  can  be  self-assembled  from  four
NA  oligos  and  it  creates  a  scaffold  that  allows  for  the
onjugation  of  four  RNA  functional  moieties  at  the  same
ime.  Functional  RNA  modules  such  as  survivin  siRNA  pre-
erved  their  target  gene  knock-down  effect  after  being  fused
o  the  X-shaped  structure  (Fig.  2C).  Branched  hexavalent
NA  nanoparticles  were  further  constructed  from  three  3WJ
otifs,  integrated  by  one  3WJ  core  motif  structure  or  by
alindrome  sequence  mediated  linking  of  two  pRNA-X  cores
113].
Recently,  Khisamutdinov  et  al.  reported  using  RNA  as
n  anionic  polymer  to  build  programmable  self-assembling
oiling-resistant  RNA  nanostructures  based  on  pRNA-3WJ
36]  (Fig.  1N).  A  triangular  shaped  RNA  nanoparticle  was
esigned  and  prepared  by  carefully  joining  extended  helices
o  the  thermodynamically  stable  pRNA-3WJ  motif  of  the
acteriophage  phi29  DNA  packaging  motor.  The  step-wise
elf-assembly  of  the  triangle  RNA  nanoparticles  was  con-
rmed  by  native  PAGE  analysis,  and  AFM  imaging  revealed
he  triangular  shape  of  the  nanoparticles  as  expected.
he  constructed  nanoparticles  are  thermodynamically  ultra-
table  and  robust.  Functional  motifs  including  siRNA,
ibozyme,  folate  and  ﬂuorogenic  RNA  aptamers  retained
heir  activities  after  conjugation  to  the  RNA  nanoparticles.
oreover,  these  RNA  triangles  could  be  used  as  building
locks  to  construct  supramolecular  complexes  such  as  RNA
exagons  and  patterned  hexagonal  arrays.  The  pRNA-3WJ
s  also  highly  tunable  [92],  the  naturally  preserved  angle
etween  the  helices  H1  and  H2  of  pRNA-3WJ  is  ∼60◦ and
his  angle  can  be  stretched  to  form  square-shaped  (90◦
ngle)  and  pentagonal  shape  (108◦ angle)  nanoparticles
ith  pre-designed  sequences  (Fig.  3A).  The  polygons  formed
y  one-step  self-assembly  manner  with  efﬁciency  >90%,  as
emonstrated  by  gel  shift  assays.  The  different  sizes  and
hapes  of  the  polygons  were  also  conﬁrmed  by  dynamic
ight  scattering  (DLS)  and  AFM.  The  equilibrium  dissocia-
ion  constants  (KD)  for  triangle,  square  and  pentagon  are
8.8  nM,  20.3  nM  and  22.5  nM,  and  the  Tm values  are  56 ◦C,
3 ◦C  and  50 ◦C,  respectively,  revealing  structure  and  shape-
ependent  thermodynamic  features.  In  a  recent  paper  by
asinski  et  al,  the  authors  showed  that  square-shaped  RNA
anoparticles  with  ﬂuorogenic  and  ribozymatic  properties  as
ell  as  different  sizes  can  be  successfully  constructed  by  uti-
izing  the  pRNA-3WJ  at  each  corner  and  different  length  RNA
uplexes  at  each  edge  of  the  square  RNA  nanoparticles  [125]
Fig.  3B).  DLS  and  AFM  determined  the  sizes  of  the  small,
edium,  and  large  square  RNA  nanoparticles  are  4.0,  11.2,
nd  24.9  nm,  respectively.  The  physiochemical  properties  of
he  nanoparticles  can  be  easily  tuned,  as  the  utilization  of
′-F  RNA  as  the  core  strand  signiﬁcantly  increased  the  melt-
ng  temperature  as  well  as  the  nanoparticle’s  resistance  to
erum-mediated  degradation.Naturally  occurring  stable  RNA-protein  complexes  were
lso  explored  as  building  blocks  for  nanostructures.  For
xample,  the  assembly  of  archaeal  box  C/D  sRNPs  com-
rising  the  L7Ae  protein  from  Archaeoglobus  fulgidus  and
RNA  as  a  stable  polymer  637
Figure  2  Construction  and  functional  assays  of  thermodynamically  stable  pRNA-(three-way  junction)  3WJ  or  pRNA-X  nanoparticles.
(A and  B)  HBV  ribozyme  assay  and  MG  aptamer  assay  of  pRNA-3WJ  nanoparticles  [123].  Adapted  with  permission  from  Ref.  [123].
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a  box  C/D  RNA  has  been  utilized  to  build  an  equilateral  tri-
angle  shaped  synthetic  RNA  protein  complex  [127]  (Fig.  1H).
The  construction  relies  on  the  interaction  between  ribo-
somal  protein  L7Ae  and  the  Kink-turn  motif  in  box  C/D
RNA.  L7Ae  can  bind  to  the  box  C/D  K-turn  motif  through
hydrogen  bonding  with  high  speciﬁcity  and  afﬁnity  [128].
It  was  reported  that  using  RNA-protein  complex  (RNP)  as
building  block  for  nanostructures  enhanced  its  stability  in
serum  comparing  to  pure  unmodiﬁed  RNA  based  nanopar-
ticles  [129].  The  RNP  nanostructure  could  be  served  as  a
scaffold  for  protein  or  RNA  functionalities.  For  example,  an
afﬁbody  peptide,  which  can  recognize  HER2  receptor,  was
connected  to  RNP  triangle  through  fusing  to  L7Ae  protein,
and  the  functionality  of  afﬁbody  peptide  was  still  retained.
siRNA  targeting  to  GFP  gene  can  be  conjugated  to  the  RNP
triangle  through  extending  the  RNA  strand  and  the  GFP  siRNA
on  RNP  nanoparticles  still  can  be  processed  by  dicer  and
knock  down  GFP  expression  in  cells.
Toolkit  IV:  RNA  origami
DNA  origami,  which  involves  the  folding  of  a  long  template
single  stranded  DNA  aided  by  multiple  short  staple  DNA
strands,  was  reported  in  2006  [130].  A  wide  range  of  2D
and  3D  nanostructures  have  been  successfully  constructed
using  the  DNA  origami  technique  [131—135].  In  2014,  a  sim-
ilar  approach  for  RNA  origami  was  reported  to  fold  single
stranded  RNA  into  RNA  tiles  and  further  assembled  into
hexagonal  lattices  [136]  (Fig.  1M).  A  variety  of  RNA  tertiary
motifs,  including  the  180◦ kissing  loop  motif  of  the  HIV-1  DIS
[137],  the  120◦ loop—loop  complex  of  RNA  i/ii  inverse  loop
R
R
t
tn  assay  of  pRNA-X  nanoparticles  [73].  Reprinted  with  permission
114],  and  the  tetraloops  GNRA  and  UNCG  [138]  were  used  to
ediate  internal  RNA  tertiary  interactions,  resulting  in  orga-
ized  and  scalable  RNA  crossover  tiles.  The  designed  RNA
rigami  nanostructures  are  also  robust,  which  could  form
y  either  annealing  or  co-transcription  on  mica.  In  contrast
o  DNA  origami,  this  RNA  origami  approach  does  not  need
hort  staple  strands  to  facilitate  the  folding  of  the  origami
tructure,  but  using  RNA  modules  such  as  kissing  loops  to
eplace  the  role  of  staple  strands.  Interestingly,  a  differ-
nt  RNA  origami  approach  which  is  a direct  extension  of
he  DNA  origami  to  RNA  was  also  reported  in  2014  [139]
Fig.  1P).  In  this  study,  a  single-stranded  RNA  scaffold  and
ultiple  staple  RNA  strands  were  used  to  assemble  deﬁned
NA  nanostructures  including  a  7-helix  bundled  RNA  tile  and
 6-helix  bundled  RNA  tube.  The  authors  also  showed  that
unctional  modules  such  as  biotin  could  be  introduced  into
he  RNA  origami  structures  by  chemical  modiﬁcations  of  the
caffold  strands.
oolkit  V:  RNA/DNA  hybrid  nanostructures
NA/DNA  hybrids  can  also  be  used  to  construct  func-
ional  nanoarchitectures.  Similar  to  split-protein  systems,
NA/DNA  hybrids  can  be  computationally  designed  for  acti-
ating  different  split  functionalities  in  the  presence  of
espective  equivalent  strands  [140—143]  (Fig.  5A).  Toe-
old  interactions  were  used  to  trigger  disassociation  of
NA/DNA  hybrids  and  re-association  of  the  double-stranded
NA  and  DNA.  The  thermodynamics  and  kinetics  of  the
oehold  interactions  can  be  tuned  to  control  the  dissocia-
ion  and  re-association  processes.  RNA  interference  modules
638  H.  Li  et  al.
Figure  3  Construction  of  RNA  polygons  based  on  pRNA-3WJ.  (A)  Construction  of  RNA  triangle,  square  and  pentagon  by  tuning  the
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pnterior pRNA-3WJ  angle  [92].  Reprinted  with  permission  from  
f RNA  squares  with  tunable  sizes  [125].  Reprinted  with  permis
s  well  as  other  functionalities  such  as  ﬂuorophores  and
NA  aptamers  can  be  successfully  triggered  inside  mam-
alian  cells.  This  RNA/DNA  hybrids  concept  has  also  been
pplied  to  other  nanostructures  such  as  nanorings  and  cubes
114,115,144—146],  and  the  spilt  functionalities  still  retain
heir  authentic  functionalities.  Because  RNA/DNA  hybrid  is
b
s
m
f[92].  Copyright  2014  Oxford  University  Press.  (B)  Construction
from  Ref.  [125].  Copyright  2014  American  Chemical  Society.
ore  enzymatically  stable  than  RNA,  this  approach  has  the
otential  to  improve  the  pharmacological  proﬁles  of  RNA-
ased  nanoparticles.  Moreover,  controlled  release  of  the
plit  functionalities  opens  a  new  avenue  for  the  develop-
ent  of  nucleic  acid-based  switches  to  modulate  cellular
unctions  in  vivo.
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increase  in  thermostability  and  enhancement  in  nucleaseRNA  as  a  stable  polymer  
Methodology  I:  Rolling  circle  transcription
Typically,  the  design  and  production  of  RNA  nanoparticles
have  relied  on  the  production  of  discrete  RNA  strands  that
can  be  assembled  in  a  controlled  and  predictive  fashion  to
generate  nanoparticles  with  a  deﬁned  structure  and  stoi-
chiometry.  Hammond  and  colleagues  have  departed  from
this  approach  with  an  innovative  strategy  that  generates
monodisperse  spherulitic  RNA  particles  from  extremely  high
molecular  weight  RNA  strands  by  using  a  rolling  circle  tran-
scription  (RCT)  approach  [147,148]  (Fig.  1J).  They  created
a  circular  DNA  construct  containing  a  siRNA  gene  without
any  terminator  sequences  and  proceeded  by  a  T7  pro-
moter.  As  a  result,  T7  RNA  polymerase  can  continuously
transcribe  the  circular  DNA  hundreds  of  times  to  gener-
ate  a  tremendous  number  of  copies  of  the  tandem  RNA
unit.  As  the  continuous  RNA  strand  is  transcribed,  magne-
sium  pyrophosphate  crystals  are  simultaneously  generated,
and  the  RNA  strands  attach  to  the  crystallite  surfaces  to
form  composite  structures;  each  structure  grows  in  length
to  become  ﬁber-like,  then,  forms  sheet-like  lamellae.  The
lamellae,  typically  ∼10  nm  thick,  ﬁnally  condense  into
spherulites  with  diameters  varying  from  a  few  micrometers
to  hundreds  of  micrometers,  referred  by  the  author  as  RNAi
microsponges.  To  achieve  efﬁcient  cellular  uptake,  PEI  was
introduced  to  condense  the  RNAi-microsponge  from  2  m  to
200  nm,  and  to  protect  the  RNA  from  degradation  by  RNase.
The  PEI  introduced  a  positively  charged  outer  layer  to  the
microsponges  to  facilitate  cell  binding  and  entry.  It  was
also  demonstrated  that  the  spherulitic  RNAi-microsponges
produced  ∼21  nt  siRNA  fragments  after  incubation  with
Dicer  and  could  transfect  a  cancer  cell  line  and  silence
ﬁreﬂy  luciferase  expression.  Gene  expression  knockdown
in  vivo  by  intratumoral  injection  of  the  PEI-condensed  RNAi-
microsponges  was  also  reported.  This  innovative  approach
opens  new  directions  to  RNA  nanoparticle  self-assembly
and  siRNA  delivery.  However,  the  therapeutic  potential  and
in  vivo  safety  of  this  approach  requires  further  evaluation,
as  PEI  has  been  shown  to  cause  well-known  adverse  side
effects,  such  as  high  cytotoxicity  [149,150].  In  addition,  fur-
ther  reduction  of  the  size  of  the  particles  is  recommended
to  avoid  non-speciﬁc  healthy  organ  accumulation.
In  material  sciences,  polymeric  membranes  are  at
the  forefront  in  the  chemical  and  biotechnology  indus-
try  because  of  their  versatile  applications  such  as  water
puriﬁcation,  dehydrogenation  of  natural  gas,  dialysis  of
blood,  removal  of  cell  particles,  and  others  [151].  Recently,
Lee’s  group  demonstrated  rolling  circle  transcription  can
also  be  applied  to  the  synthesis  of  macroscopic  RNA  mem-
branes  that  has  the  potential  as  a  controlled  drug-release
system  [152]  (Fig.  1O).  The  RNA  membrane  was  fabri-
cated  by  T7  RNA  polymerase  transcription  system  with  a
combination  of  complementary  rolling  circle  transcription
(cRCT)  and  evaporation-induced  self-assembly  (EISA).  The
circular  DNA  template  and  complementary  circular  DNA
template  were  prepared  with  long  linear  DNA  and  the  pro-
moter  DNA  for  starting  the  RCT,  respectively.  Upon  addition
of  T7  polymerase  to  these  two  circular  DNA  templates,
thousands  of  copies  of  single  stranded  RNA  and  single
stranded  complementary  RNA  were  continuously  generated.
The  two  complementary  RNA  strands  hybridized  to  each
other  thereby  forming  the  double  stranded  RNA  for  the
r
a
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arge-area  of  RNA  membrane.  After  the  cRCT  process,  the
ater  in  the  RNA  membrane  was  evaporated  and  the  dried
NA  membrane  was  concentrated  by  EISA  process.  The  self-
ssembled  RNA  membrane  was  fabricated  densely  on  the
ube  wall  during  the  evaporation  process.  The  durability
f  the  fabricated  RNA  membrane  was  tested  under  various
arsh  conditions,  including  RNase  and  DNase-rich  environ-
ents.  In  addition,  they  conﬁrmed  the  application  of  the
NA  membrane  as  an  enzyme-responsive  drug-release  sys-
em  with  doxorubicin  and  siRNA.  The  results  showed  that
he  RNA  membrane  can  provide  a  high  drug-loading  efﬁ-
iency  and  can  be  a  great  candidate  for  future  membrane
ndustry.
ethodology  II:  Chemical  modiﬁcation  of  RNA
 great  deal  of  work  on  chemical  modiﬁcations  aiming  to
mprove  the  chemical  stability  and  in  vivo  properties  of  RNA
ave  been  reported  [153—156]. Common  chemical  modi-
cations  of  RNA  can  be  categorized  into  ﬁve  classes:  (1)
odiﬁcation  of  inter-nucleotide  phosphodiester  backbone.
his  type  of  modiﬁcation  is  the  most  classic  and  simplest
ethod  to  improve  the  performance  of  RNA  in  the  biological
nvironment.  For  example,  creation  of  a  phosphorothioate
PS)  linkage  by  replacing  one  non-bridging  oxygen  atom  on
he  phosphate  backbone  with  a  sulfur  atom  substantially
ncreases  the  stability  of  RNA  in  vitro  and  in  vivo  [157].  Other
ackbone  modiﬁcations  such  as  boranophosphate,  phospho-
amidate  and  methylphosphonate  have  also  been  explored
o  enhance  the  resistance  to  nuclease-mediated  degrada-
ion  [158—160]. However,  cytotoxic  side-effects  were  also
bserved  if  extensive  modiﬁcations  were  applied  [161].
2)  Substitution  of  2′-OH  group. This  is  the  most  widely
sed  approach  since  it  is  well-tolerated,  and  can  enhance
uclease  resistance  as  well  as  reduce  immunogenicity.
or  example,  the  naturally  occurring  2′-O-methyl  (OMe)
odiﬁcation  is  nontoxic  and  able  to  prevent  immune  acti-
ation  while  conferring  biological  stability  simultaneously
161,162].  Guo’s  lab  also  reported  that  incorporation  of
′-Fluoro  nucleotides  to  pRNA  scaffold  allows  the  creation
f  stable  and  RNase-resistant  RNA  nanoparticles  with  cor-
ect  folding  and  authentic  biological  activities.  The  melting
emperature  of  2′-F  RNA  was  further  enhanced  compared
o  unmodiﬁed  RNA  [163].  The  chemically  modiﬁed  pRNA-
ased  nanoparticles  have  shown  promising  applications  in
ancer  therapy  [36,66,164—167].  Recent  study  also  showed
hat  2′-F  modiﬁed  pRNA  nanoparticles  are  resistant  to  I-125
nd  Cs-131  radiation  with  clinically  relevant  doses,  which
s  a  required  property  for  applying  these  RNA  nanopar-
icles  as  delivery  vehicles  for  targeted  radiation  therapy
168].  Other  options  for  2′-modiﬁcation  like  2′-ﬂuoro--D-
rabinonucleotide  (FANA)  have  also  shown  promise  in  gene
ilencing  applications  [169]. (3)  Locked  nucleic  acids  (LNA)
nd  unlocked  nucleic  acid  (UNA). LNA  is  another  class  of
′-modiﬁcation  in  which  2′-O  and  4′-C  is  linked  via  a  methy-
ene  bridge.  This  locked  linkage  constrains  the  ribose  ring
nto  C3′-endo  conformation  which  confers  both  signiﬁcantesistance  [170].  Successful  applications  of  LNA  such  as  2′-
mino-LNA  have  been  studied  by  Astakhova  et  al.  to  show
reat  promise  in  the  development  of  biosensor,  aptamer
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nd  other  nanomaterials  [171].  Antisense  oligonucleotides
ASO)  containing  LNA  also  has  been  reported  to  have  higher
otency  and  speciﬁcity  [172,173],  but  would  also  cause
iver  toxicity  in  mouse  models  if  LNAs  were  extensively
ncorporated  into  the  sequence[174].  In  the  other  hand,
NA  is  an  acyclic  and  structurally  ﬂexible-RNA  analogue  in
hich  the  C2′—C3′ bond  is  absent.  As  a  result,  the  bind-
ng  afﬁnity  of  UNA  towards  its  complementary  strand  is
ecreased  [175].  (4)  Modiﬁcation  of  ribonucleotide  base.
his  approach  is  less  commonly  used  than  other  modiﬁca-
ion  approaches  described  thus  far.  However,  recently  RNA
ube  nanostructures  have  been  reported  to  be  constructed
uccessfully  by  using  RNA  scaffolds  with  5-biotinylated  mod-
ﬁed  and  5-aminoallyl  modiﬁed  uracil  [139].  Other  common
odiﬁed  bases  such  as  2-thio-,  4-thio,  5-iodo-,  5-bromo-,
ihydro-,  pseudo-uracil  and  diamino-purine  also  have  been
emonstrated  to  confer  enhancement  in  stability  as  well
s  speciﬁcity  of  base-pairing  interactions  [155,176,177].
5)  Modiﬁcation  of  ribose  moiety. This  modiﬁcation  strat-
gy,  for  example,  altritol  nucleic  acid  (ANA)  and  hexitol
ucleic  acid  (HNA),  is  mainly  applied  in  siRNA  design  to
nhance  potency  and  nuclease  resistance  [178]. Besides
hese  classes,  other  novel  methods  such  as  photocaging
odiﬁcation  have  been  used  to  control  RNAi  induction  [179].
he  particular  effect  of  various  chemical  modiﬁcations  on
NA  are  summarized  in  Table  1.  It  is  expected  that  the  ratio-
al  choice  of  precise  chemical  modiﬁcations  will  greatly
ontribute  to  the  development  of  RNA  nanostructures  for
pplications  in  biomedical  sciences  and  materials  sciences.
oreover,  the  strategy  of  combining  different  modiﬁcation
pproaches  also  has  the  potential  to  improve  the  properties
f  RNA  more  dramatically.
ethodology  III:  Computational  approach
he  ﬁrst  step  in  RNA  nanoparticle  construction  is  the
onsideration  of  the  blueprint  [180].  This  requires  an  under-
tanding  of  the  assembly  and  folding  mechanism  in  the
ottom-up  assembly.  Designing  the  sequence  of  the  building
lock  is  critical  for  successful  RNA  nanostructure  assembly,
hich  can  be  achieved  by  experience  and  brainstorming
aking  into  consideration  of  RNA  folding,  complementa-
ion,  hand-in-hand  interaction,  foot-to-foot  interaction,  and
he  use  of  thermostable  motifs,  kissing  loops,  sticky  ends,
elices,  stem  loops,  etc.  All  RNA  nanoparticles  constructed
ased  on  phi29  motor  pRNA  was  achieved  via  experience  and
rainstorming  without  computer  algorithm  besides  the  tra-
itional  RNA  folding  program  developed  by  Zuker  30  years
go  [181].  It  is  expected  that  computer  algorithms  will  facil-
tate  RNA  nanoparticle  construction.  A  variety  of  computer
rograms  such  as  NanoFolder,  NanoTiler  and  RNA2D3D  are
vailable  to  facilitate  the  in  silico  design  of  RNA  sequences
these  sequences  may  contain  inter-strand  and  intra-strand
seudoknot-like  interactions)  capable  of  self-assembly  into
ulti-sequence  RNA  nanostructures  and  the  3D  modeling
f  such  structures  [182—184].  For  example,  by  utilizing
omputational  modeling  and  sequence  optimization,  three-
imensional  cubic  RNA-based  scaffolds  can  be  successfully
esigned  and  engineered  with  precise  control  over  their
hape,  size  and  composition  [144].  Moreover,  online  RNA
tructure  databases  such  as  RNAJunction  database  also
o
R
b
pH.  Li  et  al.
rovides  useful  RNA  structures  for  designing  RNA  nanostruc-
ures  [185].
pplication of RNA as a polymer in biomedical
ciences
NA  as  a  natural  and  biocompatible  polymer  has  many
dvantages  for  biomedical  applications.  It  carries  a  neg-
tive  charge  at  physiological  conditions,  which  disallows
onspeciﬁc  passing  through  negatively  charged  cell  mem-
rane.  With  the  conjugation  of  chemical  ligands  and/or
NA  aptamers,  RNA  nanoparticles  can  be  designed  for  spe-
iﬁc  cell  targeting.  It  is  less  toxic  compared  with  protein
ased  nanoparticles  since  it  can  avoid  antibody  induction
protein-free  nanoparticle),  allowing  repeated  treatment
f  chronic  diseases.  It  also  does  not  induce  an  interferon
esponse  nor  cytokine  production  [92,186].  RNA  nanoparti-
les  designed  with  a  size  range  10—40  nm  display  favorable
harmacokinetic  properties  [186], such  as  extended  half-
ife  in  vivo  (5—12  h  compared  to  0.25—0.75  h  for  siRNA),
learance:  <  0.13  L/kg/h,  volume  of  distribution:  1.2  L/kg.
urthermore,  RNA  nanoparticles  are  classiﬁed  as  chemical
rugs  rather  than  biological  entities.  This  classiﬁcation  will
acilitate  drug  approval.
As  a  building  block  for  nanoparticles,  RNA  can  be  synthe-
ized  with  deﬁned  structure  and  stoichiometry.  Multivalent
NA  nanoparticles  can  be  constructed  using  special  RNA
otifs  as  building  blocks  that  combine  therapy,  targeting,
nd  detection,  all  functionalities  in  one  particle.
NA  as  a  biocompatible  nanomaterial  for  tissue
ngineering
issue  engineering  is  a  new  area  with  lots  of  active  research
nd  some  recent  success.  Biocompatible  nanomaterials  are
eeded  for  various  applications  in  tissue  engineering,  such
s  scaffolds  or  arrays  that  can  function  as  temporary  matri-
es  and/or  niches  for  the  controlled  deposition,  inﬁltration,
roliferation,  and  differentiation  of  cells.  It  would  also  be
dvantageous  if  these  nanomaterials  could  be  highly  bio-
ompatible  and  mimic  the  natural  tissue  microenvironment
n  vivo.
Shu et  al.  reported  that  nanometer  scale  3D  RNA  arrays
an  be  assembled  by  using  pRNA  as  building  blocks  [112]
Fig.  1C).  By  rational  design,  the  authors  incorporated
alindrome  sequences  (nucleotide  sequences  that  read  the
ame  5′ →  3′ on  one  strand  and  3′ →  5′ on  the  complemen-
ary  strand)  into  the  3′-end  of  the  pRNA.  The  palindrome
equences  served  as  links  for  bridging  two  pRNAs  via  foot-on-
oot  interactions.  Loop—loop  interactions  were  further  used
o  link  pRNA  molecules  into  a  chain.  The  formation  of  pRNA
rrays  was  conﬁrmed  with  both  polyacrylamide  gel  elec-
rophoresis  (PAGE)  and  AFM.  These  RNA  arrays  are  unusually
table  and  resistant  to  a  wide  range  of  temperatures,  salt
oncentrations,  and  pH  environments.  The  microstructures
f  the  RNA  assays  are  also  tailorable  by  changing  the
NA  nucleotide  sequences.  Since  RNA  molecules  are  highly
iocompatible  and  not  toxic,  these  RNA  arrays  have  the
otential  to  be  good  tissue  engineering  scaffolds.
RNA  as  a  stable  polymer  641
Table  1  Summary  of  chemical  modiﬁcations  of  RNA.
Chemical  modiﬁcations  Advantages  Disadvantages  References
Phosphate  backbone
• Phosphorothioate  (PS)
•  Boranophosphate  (BO)
•  Phosphonoacetate  (PACE)
• Phosphoramidate
•  Methylphosphonate
•  Improve  nuclease  resistance
•  Combine  with  other
modiﬁcations  to  dramatically
improve  RNA  property
•  Destabilize  siRNA  duplexes
(e.g.  decreases  Tm by  0.5 ◦C
per PS  linkage)
•  Extensive  modiﬁcation  causes
cytotoxic  effect
[157—162]
2′-OH  group
•  Small  2′-substituents  (e.g.
2′-O-methyl  (2′-OMe),
2′-ﬂuoro  (2′-F),
2′-aminoethyl,  2′-deoxy-2′-
ﬂuoroarabinonu-cleic  acid
(2′-F-ANA))
•  Bulky  2′-modiﬁcations  (e.g.
2′-O-MOE,  2′-O-allyl)
•  Signiﬁcantly  improve
nuclease  resistance
•  Greatly  thermo-stabilizes
dsRNA  duplex  (e.g.  increase  Tm
0.5—0.7 ◦C  per  2′-OMe  and  1 ◦C
per 2′-F)
• Particularly,  2′-OMe  is
nontoxic  and  prevents  immune
activation
• Bulky  2′-modiﬁcations  can
modulate  thermo-stability  and
duplex  asymmetry,  and  also
give  higher  binding  afﬁnity
•  Extensive  or  full  modiﬁcation
will  reduce  or  fully  deactivate
siRNA  potency
• Bulky  2′-modiﬁcations  are
only  tolerated  at  limited
position  owing  to  their
distortion  of  RNA  helix
structure
[36,66,161—169,
173]
Locked  nucleic  acid  (LNA)
Unlock  nucleic  acid  (UNA)
•  LNA  enhances  the
complementary  binding  afﬁnity
and  greatly  improves
thermostability  by  2—10 ◦C  per
incorporation,  as  well  as
improves  nuclease  resistance
and  reduces  RNA
immunogenicity
• Each  UNA  destabilizes  duplex
by 5—8 ◦C  to  improve  local
destabilization  of  siRNA
duplex,  and  enhance
biostability  in  vivo
•  LNA  would  probably  cause
liver  toxicity
•  Extensive  modiﬁcation  with
LNA  and  UNA  generally  results
in decreased  activity  of  siRNA
and failure  in  annealing  of
dsRNA,  respectively
[170—175]
Ribose  moiety
• Altritol  nucleic  acid  (ANA)
• Hexitol  nucleic  acid  (HNA)
• 2′-deoxy-2′-ﬂuoroarabino-
nucleic  acid  (2′-F-ANA)
•  Cyclohexenyl  nucleic  acid
•  Enhance  thermostability  (e.g.
2′-F-ANA  increases  Tm of  RNA
duplex  by  0.5—0.8 ◦C  per
modiﬁcation)
• Improve  nuclease  resistance
•  Modiﬁcation  at  seed  region
would  slightly  reduce  siRNA
potency
[178]
Ribonucleotide  base
(5-bromo-,  5-iodo-,  2-thio-,
4-thio-uracil,  dihydro-,
pseudo,  5-biotinylated,
5-aminoallyl-uracil,
•  Stabilize  base-pairing  and  to
enhance  binding  speciﬁcity
• Particularly,  2-thio-  and
pseudo-uracil  reduce  cellular
•  Some  base  modiﬁcations  (e.g.
5-bromo-  and  5-iodo-uracil)
will  affect  siRNA  potency
[139,177]
s
c
g
t
sdiamino-purine) immune  response
RNA  nanoparticles  for  targeted  therapeutic
delivery
Targeted  delivery  is  a  major  challenge  that  nucleic  acid  ther-
apeutics  is  facing.  RNA  nanoparticles  with  chemical  ligand
and  nucleic  acid  aptamers  have  shown  great  promise  in  this
regard.  The  utilization  of  RNA  nanostructures  as  a  platform
for  targeted  therapeutics  delivery  has  been  successfully
demonstrated  by  a  series  of  studies  using  the  phi29  pRNA
t
c
t
cystem.  In  2003,  Hoeprich  et  al.  constructed  a  pRNA-based
arrier  to  deliver  hammerhead  ribozymes  [187].  Upon  conju-
ation  to  the  pRNA  5′/3′ ends,  the  HBV  ribozymes  were  able
o  fold  correctly  and  almost  completely  cleaved  the  polyA
ignal  of  HBV  mRNA  in  vitro. Targeted  therapeutics  delivery
o  speciﬁc  cancer  cells  can  be  achieved  by  using  ligand-
onjugated  RNA  nanoparticles  as  carriers.  Furthermore,
he  cargo  in  vivo  release  proﬁle  from  RNA  nanoparticles
an  also  be  controlled  through  the  rational  design  of  RNA
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anoparticles.  In  2005,  Guo  et  al.  reported  the  construction
f  chimeric  pRNA  dimer  with  one  subunit  harboring  folate
nd  the  other  subunit  harboring  a  gene  silencing  siRNA  tar-
eting  surviving  [108].  Incubation  of  these  pRNA  dimers  with
ancer  cells  resulted  in  receptor-mediated  binding  and  entry
o  cells  and  induced  efﬁcient  gene  silencing.  Animal  trials
howed  that  ex  vivo  delivery  of  the  pRNA  dimer  harboring
oth  folate  and  survivin  siRNA  could  suppress  tumor  develop-
ent.  Khaled  et  al.  studied  the  fabrication  of  a  protein-free
0—40  nm  pRNA  trimer  which  could  harbor  three  functional
odules  including  siRNA,  CD4  aptamer  or  folate  ligands
nd  a  ﬂuorescent  dye  per  nanoparticle  [111]. They  showed
hat  the  pRNA  trimer  could  also  bind  and  enter  into  cells
nd  modulate  gene  expression  and  apoptosis  both  in  vitro
nd  in  vivo.  In  2006,  Guo  et  al.,  reported  incorporating  a
olate-AMP  into  the  5′-end  of  phi29  pRNA  and  showed  that
olate  conjugated  pRNA  dimer  nanoparticles  were  able  to
eliver  survivin  siRNA  into  nasopharyngeal  epidermal  car-
inoma  cells  and  silence  the  target  gene  [188].  The  pRNA
ystem  can  also  be  used  to  deliver  anti-virus  siRNAs.  Zhang
t  al.,  developed  a  folate-linked  pRNA  conjugated  with  the
iRNA  targeting  the  Coxsackievirus  B3  (CVB3)  protease  2A
siRNA/2A)  [189].  They  observed  that  the  modiﬁed  pRNA
ould  achieve  a  similar  antiviral  effect  to  that  of  siRNA/2A
lone  and  also  strongly  inhibited  CVB3  replication.
The  latest  advance  in  the  utilization  of  phi29  pRNA
or  therapeutics  delivery  is  the  discovery  of  a  phi29  pRNA
hree-way  junction  (3WJ)  motif  with  unusual  thermody-
amic  stability.  The  slope  of  the  melting  temperature  curve
f  the  three-fragment  RNA  complex  is  close  to  90◦, indicat-
ng  extremely  low  G  of  the  phi29  pRNA-3WJ  complex  [123].
he  pRNA  3WJ  motif  was  used  as  a  RNA  scaffold  to  construct
i-,  tri-,  and  tetra-valent  RNA  nanoparticles  with  very  high
hemical  and  thermodynamic  stability  [73,123,180]. The
esulting  RNA  nanoparticles  are  resistant  to  denaturation
n  8  M  urea  and  do  not  dissociate  at  ultra-low  concen-
rations  both  in  vitro  and  in  vivo. Each  arm  of  the  3WJ
r  X-motif  can  harbor  one  siRNA,  ribozyme,  miRNA,  or
ptamer  without  affecting  the  folding  of  the  central  core,
nd  each  daughter  RNA  molecule  within  the  nanoparticle
olds  into  respective  correct  structure  with  authentic  bio-
ogical  function.  The  effects  of  gene  silencing  progressively
ncreased  with  increasing  number  of  siRNA  modules  in  the
NA  nanoparticle.  More  importantly,  systemic  delivery  of
argeting  ligand  containing  RNA  nanoparticles  into  tumor-
earing  mice  revealed  that  the  RNA  nanoparticles  remained
ntact  in  vivo  without  showing  any  sign  of  dissociation  or
egradation.  These  RNA  nanoparticles  can  speciﬁcally  tar-
et  subcutaneous  tumor  xenografts  [73,123,167],  as  well
s  orthotopic  breast  cancer  [173]  and  intracranial  glioma
umors  [164]  without  detectable  accumulation  in  liver,  lung
r  other  healthy  organs  or  tissues  (Fig.  4A—C).  A  recent
tudy  also  showed  that  the  pRNA-3WJ  nanoparticle  conju-
ated  with  folate  can  speciﬁcally  target  colorectal  cancer
etastasis  in  the  liver,  lungs  and  lymph  node  simulta-
eously  in  vivo, without  accumulation  in  normal  liver  or
ung  parenchyma  [165]  (Fig.  4D).  Pharmacological  analy-
is  in  mice  indicated  that  the  pRNA  nanoparticles  display
avorable  pharmacokinetic  (PK)  and  pharmacodynamic  (PD)
roﬁles,  with  in  vivo  half-life  extended  10-fold  compared  to
iRNA  alone  and  did  not  induce  adverse  immune  response
ncluding  cytokine,  interferon,  antibody,  and  other  toxic
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ffects  [186].  The  regression  of  gastric  cancer  and  breast
ancer  by  RNA  nanoparticles  harboring  siRNA  [73,123,167]
r  anti-miRNA  [173]  has  also  been  reported  recently.
A  recent  paper  also  reported  the  development  of  novel
mmunomodulators  by  engineering  rationally  designed  RNA
olygonal  nanoparticles  [92].  When  immunological  adju-
ants  CpG  DNA  were  incorporated  into  the  RNA  polygons,
otent  immunostimulation  (cytokine  TNF- and  IL-6  induc-
ion)  was  observed  both  in  vitro  and  in  vivo, compared  to
ontrols.  Moreover,  the  RNA  nanoparticles  could  deliver  CpG
NA  to  macrophages  speciﬁcally  and  the  degree  of  immuno-
timulation  signiﬁcantly  depended  on  the  size,  shape,  and
he  number  of  payload  per  RNA  nanoparticle.  This  ﬁnding
emonstrates  that  RNA  nanotechnology,  such  as  developing
NA  nanoparticles  based  on  pRNA,  has  great  potential  to
evelop  novel  immunomodulators.
NA  nanoparticles  for  controlled  drug  delivery
any  pre-clinical  studies  are  evaluating  RNAi  as  novel  thera-
eutics  for  different  diseases.  However,  one  concern  is  that
ingle  gene  targeted  therapy  might  eventually  fail  due  to
utations  over  time  or  development  of  alternative  signaling
ascades  or  escape  pathways.  Multivalent  RNA  nanoparti-
les  can  be  a  very  promising  vehicle  for  delivery  of  multiple
iRNAs  to  suppress  multiple  genes  simultaneously.  A  recent
ublication  by  Afonin  et  al.  showed  that  several  RNA  and
NA/DNA  nanocubes  could  be  functioned  with  multiple  dou-
le  stranded  RNAs  and  the  siRNAs  can  be  conditionally
eleased  through  ssDNA  toehold-mediated  interactions.  Fur-
hermore  the  RNA  nanocubes  can  be  tracked  intracellularly
hrough  FRET  (Förster  resonance  energy  transfer)  stud-
es  using  ﬂuorophores  [190].  In  addition,  spherical  nucleic
cid  (SNA)  nanoparticle  conjugates  developed  by  Mirkin
roup  have  also  shown  promise  for  systemic  siRNA  deliv-
ry  for  treating  diseases  such  as  glioblastoma  [191,192]
Fig.  5D).  In  vivo  studies  on  glioma-bearing  mice  showed
hat  SNA  nanoparticle  conjugates  targeting  the  oncoprotein
cl2Like12  effectively  increased  intratumoral  apoptosis,
nd  reduced  tumor  burden  and  progression  without  adverse
ide  effects  [192].
DNA  origamis  have  been  exploited  as  a carrier  for  chem-
cal  drug  doxorubicin  through  noncovalent  intercalation
nteractions.  The  DNA  origami/doxorubicin  nanoparticles
ere  able  to  enter  into  doxorubicin-resistant  cancer  cells
nd  circumvent  their  drug  resistance  [193].  Furthermore,
he  DNA  origami/doxorubicin  nanoparticles  showed  a  slow
rug  release  proﬁle  at  pH  7.4  under  physiological  condi-
ions  but  showed  enhanced  release  capability  in  pH  5.5
orresponding  to  tumor  subcellular  organelles  [194].  As
e  discussed  in  previous  section,  RNA  origami  structures
ave  been  reported  [136].  With  favorable  thermodynamic
tability  and  excellent  serum  stability  after  chemical  modi-
cations,  RNA  origami  is  expected  to  be  more  favorable  than
ts  counterpart  DNA  origami  as  a  drug  carrier  for  achieving
ontrolled  drug  release.NA  nanoparticles  for  vascular  targeting
 critical  feature  to  drug  delivery  is  the  transportation  of
herapeutics  to  their  intended  target  sites.  Arguably,  as
RNA  as  a  stable  polymer  643
Figure  4  pRNA  nanoparticles  for  cancer  targeting.  (A)  pRNA-3WJ  nanoparticles  target  folate-receptor  positive  tumor  xenografts
[123].  Reprinted  with  permission  from  Ref.  [123].  Copyright  2011  Nature  Publishing  Group.  (B)  pRNA-3WJ  nanoparticles  target  glioma
[164].  Reprinted  with  permission  from  Ref.  [164].  Copyright  2015  Impact  Journals,  LLC.  (C)  pRNA-X  nanoparticles  target  folate-
receptor positive  tumor  xenografts  [73].  Reprinted  with  permission  from  Ref.  [73].  Copyright  2012  Elsevier.  (D)  pRNA  nanoparticles
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atargeting colorectal  cancer  metastases  [165].  Reprinted  with  per
almost  all  cells  in  the  body  are  within  ∼100  m  of  the  vas-
culature,  and  by  way  a  vascular  endothelial  cell,  it  stands  to
reason  that  the  vascular  delivery  route  represents  the  most
promising  mean  of  any  site  speciﬁc  delivery  strategy  [195].
Owing  to  the  signiﬁcant  heterogeneity  in  endothelial  cells,
both  temporally  and  regionally,  it  has  been  observed  that
the  vascular  endothelium  has  unique  expression  of  surface
markers  that  are  highly  regionally  variant.  In  other  words,  it
is  potentially  possible  to  target  unique  endothelial  zip  codes
to  locally  accumulate  nanocarriers  [196].
Current  strategies  for  vascular  targeting  of  nanocarriers
have  primarily  focused  on  antibody  and  peptide  based
strategies,  targeting  to  surface  markers  CD31  (PECAM-1)
H
d
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aion  from  Ref.  [165].  Copyright  2015  American  Chemical  Society.
197,198],  inﬂammatory  markers  (ICAM-1,  VCAM-1)
199—204],  and  thrombomodulin  [205].  Targeting  of
D31,  ICAM1  and  VCAM  represents  a  unique  opportunity
s  their  binding  of  nanoparticles  to  their  sites  highlights
 novel  endocytic  mechanism,  CAM  mediated  endocytosis
198,206].  The  use  of  antibodies  as  targeting  agents  is
echnically  challenging  owing  to  their  size,  cost  of  produc-
ion  and  potential  immune  responses.  RNA  aptamers  have
lready  shown  exciting  advantages  in  vasculature  targeting.
igh  afﬁnity  aptamers  (56  pM)  against  P-selectin  have  been
eveloped  [207]. Microbubbles  coated  with  a  low  density
1000  copie/m2)  of  P-selectin  aptamers  demonstrated  high
dhesion  even  under  shear  rates  as  high  as  1700  L/s.  The
644  H.  Li  et  al.
Figure  5  Functional  RNA  nanostructures  for  therapeutics  delivery  and  medical  detection.  (A)  Triggered  siRNA  delivery  based  on
RNA/DNA hybrid  nanostructures  [140].  Reprinted  with  permission  from  Ref.  [140].  Copyright  2013  Nature  Publishing  Group.  (B)
QD-aptamer-doxorubicin  conjugate  nanoparticles  as  a  cancer-targeted  imaging,  sensing  and  treatment  platform  [210].  Reprinted
with permission  from  Ref.  [210].  Copyright  2007  American  Chemical  Society.  (C)  PSMA  aptamer-conjugated  gold  nanoparticles  for
targeted molecular  CT  imaging  and  therapy  of  prostate  cancer  [213].  Reprinted  with  permission  from  Ref.  [213].  Copyright  2010
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ef. [191].  Copyright  2014  American  Chemical  Society.
eal  promise  of  vascular-targeted  RNA  nanoparticles  comes
rom  the  combination  of  the  high  binding  afﬁnity  to  carrier
izes  below  70  nm.  The  capillary  bed  represents  the  greatest
romise  of  vascular  targeting,  where  there  already  exists  a
ighly  active  transcytosis  mechanism,  with  approximately
en  thousand  times  more  caveolae  than  other  endothelial
ells  [208].  These  70  nm  endocytic  vesicles  are  an  exciting
arget  for  drug  delivery  [209]  yet  require  a  carrier  system
ike  RNA  nanoparticles  that  are  simultaneously  small  and
ave  high  afﬁnity  to  permit  transcytosis  and  tissue  bed
elivery.
NA  nanoparticles  as  non-invasive  medical
etection  reagents
unctional  RNA  structures  such  as  aptamers  can  be  used
or  developing  non-invasive  molecular  and  cellular  imaging
eagents  which  may  have  applications  in  the  diagnosis  of
arious  diseases  including  cancer,  cardiovascular  diseases,
nd  infectious  diseases.  Considering  it  is  relatively  easy  to
onjugate  a  ﬂuorophore,  radionuclide,  quantum  dot  (QD),
old  nanoparticle,  or  other  imaging  functional  groups  to
t
a
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aading  RNA  therapeutics  [191].  Reprinted  with  permission  from
NA,  RNA  molecules  with  high  binding  afﬁnity  to  their  tar-
ets  hold  great  potential  as  a  platform  to  construct  imaging
robes  which  can  speciﬁcally  detect  their  targets  in  vitro
nd  in  vivo.
Fluorescent  RNA  nanoparticles  conjugated  with  aptamer
ave  been  widely  explored  for  cancer  detection.  For
xample,  Bagalkot  et  al.  [210]  developed  a  QD-aptamer-
oxorubicin  conjugate  nanoparticle  as  a  cancer-targeted
maging,  sensing  and  treatment  platform  (Fig.  5B).  A10
NA  aptamer,  which  speciﬁcally  binds  to  the  extracellular
omain  of  the  prostate  speciﬁc  membrane  antigen  (PSMA),
as  conjugated  to  the  surface  of  ﬂuorescent  quantum
ots  and  the  anticancer  drug  doxorubicin  was  intercalated
nto  the  double-stranded  stem  of  the  A10  aptamer.  In  the
onjugate  nanoparticle,  ﬂuorescence  of  doxorubicin  was
uenched  by  the  aptamer  through  donor-quencher  FRET,
nd  the  ﬂuorescence  of  QD  was  quenched  by  DOX  through
onor-acceptor  FRET  mechanism.  When  the  nanoparticle
nters  the  prostate  cancer  cell  and  doxorubicin  is  released,
he  ﬂuorescence  of  QD  and  DOX  is  re-activated.  Other  RNA
ptamers  conjugated  with  ﬂuorescent  dye  chemicals  have
lso  been  utilized  for  breast  cancer  diagnosis,  such  as  EpCAM
ptamer  labeled  with  DY647,  TYE665  or  FITC  [211].
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aRNA  as  a  stable  polymer  
Conjugating  RNA  aptamer  with  radioactive  material  can
also  be  applied  as  diagnostic  radiopharmaceuticals  to  detect
cancer  cell  markers.  In  a  recent  study  reported  by  Gomes
et  al.  [212]  a  36  nucleotide  long  truncated  RNA  aptamer
with  2′F  pyrimidine  and  2′-O-methyl  purine  modiﬁcation  was
constructed  for  targeting  to  the  human  matrix  metallopro-
tease  9  (hMMP-9),  which  promotes  tumor  metastasis  and
is  an  important  marker  of  malignant  tumors.  The  5′-end
amine  modiﬁed  RNA  aptamer  was  conjugated  to  MAG3-NHS,
which  served  as  a  chelator  for  Technetium-99m  (99mTc).  The
99mTc  labeled  modiﬁed  RNA  aptamer  was  able  to  speciﬁcally
detect  its  target  in  human  brain  tumors  with  autoradiogra-
phy.
With  the  conjugation  of  the  PSMA  RNA  aptamer  to  the
surface  of  gold  nanoparticles  (GNPs)  [213],  a  targeted
computed  tomography  (CT)  imaging  and  therapy  system
for  prostate  cancer  can  also  be  established  (Fig.  5C).
The  CT  imaging  study  revealed  that  the  PSMA  aptamer-
conjugated  GNPs  could  generate  more  than  four-fold  greater
CT  intensity  for  a  PSMA-expressing  cell  line  than  a  non-PSMA-
expressing  cell  line,  suggesting  good  speciﬁcity  in  detection
of  the  targeted  cancer  cells.
RNA  nanoparticles  for  intracellular  imaging  and
detection
An  interesting  example  of  applying  RNA  in  intracellular
imaging  is  the  Spinach  RNA  aptamer,  which  is  the  RNA
mimic  of  Green  ﬂuorescent  protein  (GFP).  GFP  has  been
extensively  utilized  as  a  reporter  protein  in  cell  and  molec-
ular  biology.  Similarly,  the  RNA  mimics  of  GFP  should  also
have  remarkable  applications  in  biomedical  research,  espe-
cially  for  intracellular  imaging  of  RNA.  By  using  the  method
of  systematic  evolution  of  ligands  by  exponential  enrich-
ment  (SELEX),  Paige  et  al.  developed  a  novel  class  of  RNA
aptamers,  termed  Spinach  that  bind  to  ﬂuorophores  resem-
bling  the  ﬂuorophore  in  GFP  [214]  (Fig.  6A).  Upon  binding
of  the  targeted  ﬂuorophores,  these  RNA  aptamers  were
capable  of  emitting  tunable  ﬂuorescence  with  comparable
brightness  to  enhanced  GFP  (EGFP)  and  many  other  ﬂuo-
rescent  proteins.  Moreover,  the  RNA-ﬂuorophore  complex  is
resistant  to  photobleaching.  Interestingly,  the  Spinach  RNA
aptamer  can  be  expressed  in  vivo  by  fusing  to  other  cellular
RNAs,  for  example,  5S  RNA,  to  enable  live-cell  imaging  and
monitoring  of  these  cellular  RNAs.  Furthermore,  ﬂuorescent
sensors  for  detecting  a  variety  of  small  molecules  and  cel-
lular  metabolites,  including  adenosine  5′-diphosphate  (ADP)
and  S-adenosylmethionine  (SAM),  in  vitro  and  in  living  cells
could  also  be  generated  by  combining  the  Spinach  aptamer,
a  transducer,  and  a  target-binding  aptamer  [215]  (Fig.  6B).
Reif  et  al.  [216]  recently  reported  another  novel  method
to  enable  real-time  monitoring  of  RNA  folding  and  degra-
dation  in  living  cells  based  on  the  pRNA-3WJ.  The  authors
designed  and  constructed  RNA  nanoparticles  by  incorporat-
ing  an  RNA  aptamer  capable  of  binding  to  malachite  green
(MG),  the  hepatitis  B  virus  ribozyme  and  the  luciferase  siRNA
into  the  pRNA  3WJ.  When  MG  aptamer  binds  to  MG  dye,  it
will  emit  ﬂuorescent  light  only  if  the  aptamer  folds  correctly.
The  MG  aptamer  system  can  then  be  used  to  monitor  the
degradation  of  the  constructed  RNA  nanoparticles  by  ﬂuo-
rescent  microscopy  and  ﬂuorescence  spectroscopy.  By  using
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his  novel  design,  the  authors  determined  the  half-life  (t1/2)
f  the  MG  aptamer  containing  pRNA-3WJ  inside  living  cells
o  be  ∼4.3  h.
NA  as  a  polymer  for  biosensor  systems
he  biomolecular-based  detection  system  has  been  widely
nvestigated  in  many  applications  including  clinical  diag-
osis,  food  industry,  environmental  monitoring  industry,
nd  security  industry  [217,218].  Conventionally,  biosensors
an  detect  proteins,  nucleic  acids  such  as  DNA  or  RNA
equences,  small  organic  molecules,  and  others  [218—220].
NA  molecules  are  well  suited  to  serve  as  detection  tools
or  small  molecules,  for  example,  antibiotics,  peptides,
etal  ions,  ligands,  etc.  [221,222]  because  of  their  unique
olding  structures,  functional  conformation,  predictable
ase-pairing,  and  high  ﬁdelity.  These  characteristics  of  RNA
llow  for  the  development  of  ribozyme  or  aptamer,  and
ptazyme-based  biosensors  [223—225].  Also,  as  the  target,
NA  can  be  used  to  develop  the  biosensor  for  the  detection
f  messenger  RNA  or  micro  RNA  [226—229].  Various  detec-
ion  methods  of  RNA-based  biosensors  were  proposed  such  as
lectrochemical  type,  ﬂuorescence  type,  optical  type,  and
lectrical  type.  Also,  there  are  various  detection  platforms
or  RNA-based  biosensors  (Fig.  7)  [230—235].  In  this  section,
e  brieﬂy  introduce  RNA-based  biosensors  for  biomedical
nd  environmental  monitoring  applications.
The  ﬁrst  proof  of  concept  of  using  RNA  in  a  biosen-
or  was  developed  by  Breaker  Group  [221].  Self-cleaving
ammerhead-ribozymes  were  created  with  seven  differ-
nt  RNA  switches  and  these  immobilized  each  pixel  that
esponded  allosterically  to  six  types  of  analytes  (Co2+,
GMP,  cCMP,  cAMP,  FMN  and  theophylline).  The  platform
f  biosensor  array  was  prepared  on  a  polystyrene  cell  cul-
ure  plate  which  was  coated  with  gold  by  physical  vapor
eposition.  The  ribozyme  was  immobilized  onto  gold  sur-
ace  via  a 5′-thiotriphosphate-terminated  RNA  moiety.  Then,
ach  hammerhead  ribozymes  cleaved  off  their  3′ frag-
ent  according  to  addtion  of  individual  analytes.  They  also
howed  the  quantitave  and  qualitive  measurement  of  cAMP
n  culture  media  from  E.  coli  strand.
RNA  can  also  serve  as  the  detection  analytes  to  detect
iable  E.  coli  as  an  indicator  organism  in  drinking  water,
hich  was  proposed  by  Baeumner  group  [228,229].  This
NA-based  biosensor  was  generated  with  the  extraction  and
mpliﬁcation  of  mRNA  molecules  from  E.  coli  in  20  min.
iable  E.  coli  in  the  water  were  identiﬁed  and  quantiﬁed
sing  a  200  nt  target  sequence  from  mRNA.  The  detec-
ion  limit  of  the  biosensor  system  could  detect  around
0  viable  E.  coli  in  water  (5  fmol  per  sample)  using  the
lectrochemiluminescence  (ECL)  detection  method.  They
ntroduced  the  isothermal  ampliﬁcation  technique,  a nucleic
cid  sequence-based  ampliﬁcation  (NASBA)  for  mRNA  ampli-
cation.
RNA  was  also  applied  to  develop  medical  diagnosis
iosensors.  Theophylline  (1,3-dimethylxanthine)  is  a  com-
on  agent  in  the  bronchodilators  and  used  for  acute
nd  chronic  asthma.  Gothelf  group  developed  a  RNA-
ased  electrochemical  biosensor  for  theophylline  in  serum
ith  a  ferrocence  (Fc)  redox  probe  [225,233].  In  this
tudy,  the  thiol  group-modiﬁed  and  amino  group-modiﬁed
NA  aptamer  was  immobilized  onto  gold  substrate  via
646  H.  Li  et  al.
Figure  6  Spinach  RNA  aptamer  for  intracellular  imaging  and  sensing.  (A)  Live-cell  imaging  of  Spinach-tagged  5S  RNA[214].
Reprinted with  permission  from  Ref.  [214].  Copyright  2011  The  American  Association  for  the  Advancement  of  Science.  (B)  Imaging
cellular metabolites  in  E.  coli  with  sensor  RNA[215].  The  sensor  RNA  comprises  Spinach  (black),  a  transducer  (orange),  and  a  target-
binding aptamer  (blue).  Reprinted  with  permission  from  Ref.  [215].  Copyright  2012  The  American  Association  for  the  Advancement
of Science.
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ovalent  bonding  between  thiol  group  and  gold  substrate.
hen,  the  Fc  redox  probe  was  covalently  attached  to  the
′-amino  group  of  RNA  aptamer  through  Fc-caroxylic  acid
HS  reaction.  Usually,  the  RNA  aptamer  stays  on  the  open
onformation  in  absence  of  theophylline.  However,  when
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he  theophylline  added  to  RNA  apatmer-modiﬁed  electrode,
he  aptamer  folds  into  the  conformationally  restricted  hair-
in  strucutre.  As  a  result,  this  phenomenon  changed  the
lectron  transfer  that  was  monitored  by  cyclic  and  differ-
ntial  pulse  voltammetry.  Moreover,  speciﬁc  recognition  of
RNA  as  a  stable  polymer  647
Table  2  Classiﬁcation  of  RNA  polymer-based  bioelectronics.
RNA-based  bioelectronics  References
Biocomputation  devices Biologic  gate  [238,243]
Biomemory  [238,243,266]
Bioinformation  processor  [242,243,245,247,248,250]
Biosensors Biomedical  Sensor  [215,217,221,222,225—227]
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dopamine  by  the  RNA  aptamer  allows  selective  amperomet-
ric  detection  of  dopamine  from  100  nM  to  5  M  range  in  the
presence  of  competitive  neurotransmitters  such  as  catechol,
epinephrine,  norepinephrine,  and  others  [232].
In  an  alternative  approach,  Hammond  group  used  a  RNA-
based  ﬂuorescent  biosensors  for  detecting  the  cyclic  di-GMP
and  cyclic  AMP-GMP  [226].  The  c-di-GMP  was  generated
by  a  GEMM-I  riboswitch  aptamer  and  the  riboswitch  ligand
mutation  can  recognize  the  c-AMP-GMP,  c-di-GMP.  The  ﬂu-
orescence  turn-on  was  activated  by  the  DFHBI  ﬂuorescent
molecule  for  cell  imaging.  This  system  provided  selective
and  sensitive  detection  for  each  cyclic  dinucleotide.  Thus,
there  are  many  examples  demostrating  that  RNA  molecules
are  promising  candidates  for  biosensor  applications.
Application of RNA as  a polymer in material
sciences
RNA  as  a  polymer  for  biocomputation  systems
Silicon-based  computer  systems  are  ubiquitous  [236]  but
new  processors  to  implement  computation,  communication,
and  controls  are  needed  to  meet  the  demands  of  vari-
ous  applications.  Gordon  Moore’s  Law  suggested  that  due
to  the  increasing  demand  of  the  memory,  computer  elec-
tronic  devices  on  the  microprocessor  will  be  doubled  every
18  months.  Scientists  and  engineers  are  wondering  whether
current  computer  technology  growth  can  be  continued  in  the
next  ten  years.  They  raised  the  concern  that  silicon  micro-
processor  speed  and  miniaturization  will  eventually  reach
limits  by  current  technology.  Thus,  molecular-scale  com-
puting  has  been  explored  since  1994  due  to  the  predictable
ending  of  Moore’s  Law  for  silicon-based  computer  devices.
In  the  last  few  decades,  biotechnology  has  been  inte-
grated  with  nanotechnology  and  electrical  engineering
t
m
l
t
Figure  8  Advantages  of  RNAsensor  [228,229]
237—239].  As  a  result,  the  ﬁeld  of  bioelectronics  has
een  created  [240,241].  Bioelectronics  has  led  to  the
evelopment  of  the  nanoscale  biochip,  biosensor,  and  bio-
omputation  devices  such  as  information  storage  devices,
ogic  gates,  ﬁeld-effect  transistors  and  computation  sys-
ems  (Table  2) [242—245].  Typically,  bioelectronic  devices
re  composed  of  a  biological  actuation  portion,  and  an
lectronic  signal  transduction  portion.  So  far,  the  biologi-
al  component  is  usually  composed  of  biomolecules,  such
s  protein  and  DNA  [239,242,244]. Recently,  some  pioneer-
ng  groups  have  suggested  that  the  RNA-based  bioelectronic
evices  also  exhibited  the  logic  gate  behavior,  processing
unctions,  and  biocomputations  [180,246—250]. The  advan-
ages  of  RNA-based  computation  are  summarized  in  Fig.  8.
iocomputation  approaches  for  information  control,  stor-
ge,  and  processing  using  RNA-based  devices  brings  new
ossibilities  that  embody  multiple  functions  in  biological  sys-
ems.  The  development  of  biological  computers  composed
f  artiﬁcial  RNA  molecules  to  operate  inside  living  cells
r  tissues  would  provide  a new  avenue.  A  combination  of
hese  results  will  pave  the  way  to  develop  the  new-concept
f  biocomputer  development  in  the  future  such  as  tissue-
imicked  computations.
NA  as  a  polymer  for  logic  gates
n  computer  science,  the  ‘logic’  term  is  deﬁned  as  cir-
uits  which  gives  an  output  corresponding  to  a  set  of  two
nput  values  (True  ‘1’,  High  voltage  and  False  ‘0’,  Low  volt-
ge).  The  logic  gate  is  required  to  have  two  input  values
or  performing  Boolean  function  [241].  Thereby,  it  gives
he  logical  output  to  perform  the  next  function.  Usually,
an-made  computers  consist  of  millions  of  combinational
ogic  gates.  Thus,  logic  gates  are  essential  components  of
he  computer.  As  aforementioned,  in  the  last  few  decades,
-based  biocomputation.
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he  concept  of  a  biomolecule-based  computation  system
as  been  proposed  or  explored  to  solve  the  current  lim-
tation  of  silicon-based  computations  [246,251—255]. The
rst  attempt  of  molecular-scale  computation  was  devel-
ped  by  Adleman’s  group  in  1994  [251]. They  introduced
he  encoded  DNA  molecule  to  solve  the  Hamiltonian  path
roblem.  This  research  established  a  milestone  for  the
eld  of  biomolecule-based  computations.  Since  then,  sev-
ral  groups  proposed  the  DNA  polymer-based  logic  systems
252,254,255].  The  basic  operation  mechanism  of  DNA-based
ogic  gate  is  combinational  DNA  hybridization  that  undergoes
onformational  change  or  chemical  reaction  and  includes
H,  temperature,  light,  electrical,  or  electrochemical  sig-
als  [251—255].  The  function  of  logic  gate  gives  the  discrete
tate  change  such  as  structure,  ﬂuorescence,  absorbance,
nd  electrochemical  or  electrical  current  as  the  output.
ike  this,  the  various  types  of  DNA-based  computations  have
een  proposed.  DNA,  however,  is  hard  to  use  to  perform  the
omplex  functions  because  of  its  simple  functionality.  To
evelop  the  new-concept  of  biocomputation  systems,  RNA
s  a  candidate  owing  to  its  intriguing  characteristics.  The
olding  and  assembly  of  RNA  molecules  drive  themselves
nto  secondary  and  tertiary  structures  using  the  formation  of
airpin  loops,  dovetails,  bulges,  and  internal  loops,  etc  [10].
hereby,  RNA  has  functionality  such  as  aptamer,  ribozyme,
iRNA,  non-coding  RNA,  circular  RNA,  etc.  [180]  These  var-
ous  functional  groups  can  be  easily  applied  to  the  new
oncept  of  logic  gate  behavior,  information  storage,  infor-
ation  processing,  and  computations  as  the  novel  elements
256—264].
An  autonomous  biomolecular-based  computer  has  been
roposed  to  regulate  the  gene  expression  ‘‘logically’’  [248].
he  basic  computation  rule  is  governed  by  ‘diagnostic  rule’
or  prostate  cancer  state  detection.  If  the  speciﬁc  genes
elating  to  prostate  cancer  are  overexpressed,  then  ssDNA
ill  bind  to  their  mRNA  and  inhibits  the  protein  synthesis.
he  level  of  speciﬁc  RNA  and  the  concentration  of  spe-
iﬁc  molecule  which  regulates  the  point  mutations  were
egarded  as  an  input.  The  release  of  short  ssDNA  modu-
ated  the  levels  of  gene  expression  for  anticancer  activity,
s  the  output  logically.  The  computation  module  has  two
tates,  ‘‘positive’’  and  ‘‘negative’’,  in  response  to  the  level
f  speciﬁc  gene  expression.  This  biocomputation  concept  is
elated  with  the  identiﬁcation  of  mRNAs  of  disease-related
enes.  Thereby,  it  can  be  applied  to  cancer  diagnosis  systems
ased  on  logic  analysis.
A  RNAi-based  logic  evaluator  has  also  been  reported  to
erform  Boolean  logic  corresponding  to  input  molecules  in
he  human  kidney  cells  [249].  The  reported  biological  circuit
s  composed  of  several  mRNA  species  that  encode  the  same
rotein  but  have  different  non-coding  regions.  This  protein
erved  as  the  output.  As  an  input,  siRNAs  were  used  to  con-
rol  the  degradation  of  the  target  mRNA  and  the  expression
f  the  output  protein.  Expressions  with  up  to  ﬁve  logic  vari-
bles  were  directly  evaluated  by  this  system.
NA  as  a  polymer  for  information  processorn  computer  sciences,  the  information  processor  is  a  unit
hat  receives  the  input  information  and  processes  it  into
nother  form  based  on  programmed  functions.  RNA-based
m
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nformation  processing  devices  that  operate  logic  gates,  sig-
al  ﬁltering,  and  cooperativity  functions  have  been  reported
250,259,265].  RNA  devices  composed  of  ribozymes  and  RNA
ptamers  received,  processed  and  transmitted  the  molecu-
ar  inputs  to  express  the  green  ﬂuorescent  protein  as  output.
s  a  sensor  part,  the  RNA  aptamer  was  introduced  and  a
ammerhead  ribozyme  was  used  to  process  the  cleaving  of
he  aptamer.  Also,  the  transmitter  part  was  composed  of
equences  that  bind  to  the  aptamer  and  ribozymes.  It was
uggested  that  the  RNA  aptamer  and  ribozyme  combina-
ion  can  be  used  as  actuating  elements  for  multi-functional
nformation  processor  development  [250,265].
An  intracellular  RNA  computation  device  in  a  single  mam-
alian  cell  has  also  been  reported  [259].  Trigger-controlled
ranscription  factors  were  used  to  regulate  the  gene  expres-
ion  individually  and  the  RNA-binding  protein  was  used  to
nhibit  the  translation  of  transcripts  on  target  RNA  motifs.
his  computation  biosynthetic  circuit  can  provide  the  NOT,
ND,  NAND,  and  N-IMPLY  expression  functions  in  individual
ells.  Moreover,  two  N-IMPLY  expression  functions  can  com-
ine  with  other  cells  to  operate  XOR  gate  functions  and  three
ogic  gates  can  perform  the  half-adder  and  half-subtractor
unctions  for  arithmetic  calculation.
NA  as  a  polymer  for  resistive  biomolecular
emory
NA  can  also  provide  several  advantages  such  as  ease  of
onstruction,  well  deﬁned  structure  and  thermodynamic
tability  for  the  development  of  biomolecular  memory
evices.  Based  on  the  discovery  of  the  ultra-high  ther-
ostable  pRNA-3WJ,  a  pRNA-3WJ/QD  hybrid  nanoparticle
or  resistive  biomolecular  memory  application  has  been  con-
tructed  [266].  The  QD  was  used  as  a  semiconducting  part  for
torage  of  the  electrons  and  pRNA-3WJ  was  used  as  an  insu-
ating  part  and  serves  as  the  bridge  between  QD  and  metal
ubstrate.  The  electrical  measurement  (I—V)  was  conducted
o  this  hybrid  structure  for  resistive  memory  performances.
his  study  showed  the  RNA  polymer  conjugates  can  be  used
irectly  for  molecular  memory  device  fabrication.
ybrid  RNA  polymers  as  semiconductors
iomolecular  hybrids  of  a conducting  polymer  [poly(O-
ethoxy  aniline)  (POMA)]  and  dsRNA  have  been  reported
s  semiconductors  [267].  Fourier  transform  infrared  spec-
roscopy  (FTIR)  indicated  that  these  hybrid  polymers  are
eld  together  by  electrostatic,  H-bonding,  and  pi—pi  inter-
ctions.  The  circular  dichroism  spectra  of  the  hybrid
olymers  indicated  that  the  dsRNA  underwent  a  small  dis-
ortion  in  conformation  from  the  canonical  A-form  towards
he  B-form  during  the  formation  of  the  hybrid  polymers.  TEM
icrographs  revealed  that  these  polymers  create  a  ﬁbrillar
etwork  structure.  The  conductivity  values  of  the  POMA-RNA
ybrids  were  three  orders  of  magnitude  higher  than  that  of
NA  alone.  The  I—V  curves  of  the  POMA-RNA  hybrid  poly-
ers  also  demostrated  a  semiconducting  nature.  Based  on
hese  physical  characteristics,  the  POMA-RNA  hybrids  have
he  potential  to  be  candidates  for  fabricating  biosensors  for
ther  applications.
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Conjugation  of  RNA  to  graphene
Graphene  is  a  one-atom  thick,  two-dimensional  honeycomb
lattice  composed  of  sp2-bonded  carbon  atoms.  It  can  be
used  as  a  fundamental  building  block  for  constructing  other
graphite-based  structures  such  as  fullerenes  and  nanotubes
[268,269].  This  newly  discovered  carbon-based  material  has
been  a  popular  subject  in  material  science  and  nanotechnol-
ogy.  It  has  been  used  for  the  sensing  of  a  toxin  Microcystin-LR
in  water  [270—273].  RNA  aptamer  have  been  covalently
immobilized  on  graphene  oxide  and  a  polydispersed  sta-
ble  RNA-graphene  oxide  nanosheet  have  been  constructed
[274].  The  RNA  attached  to  these  nanosheets  was  resistant
to  nuclease  degradation  and  the  nanosheets  competitively
absorbed  trace  amounts  of  the  peptide  toxin  microcystin-
LR  from  drinking  water.  PEI-grafted  graphene  oxide  was  also
used  to  deliver  short  interfering  RNA  (siRNA)  as  well  as  anti-
cancer  drug  doxorubicin  to  cancer  cells  [275].  RNA  has  also
been  used  as  a  surfactant  to  exfoliate  ﬂakes  of  graphene
from  nanocrystalline  graphite  to  produce  transparent  and
conducting  RNA-graphene-based  thin  ﬁlms  [276],  which  has
a  potential  for  a  variety  of  electronic  applications.  Further
research  in  RNA-graphene  nanocomposites  may  open  a  new
avenue  towards  many  applications  of  graphene-based  con-
ductive  materials.
Conjugation  of  RNA  with  other  nanoparticles
The  conjugation  of  a  RNA  with  nanoparticles  such  as  quan-
tum  dot,  iron  oxide  nanoparticle  or  gold  nanoparticle  has
been  successfully  demonstrated  by  a  series  of  studies  for
nanosized  imaging,  therapy  and  diagnosis  [277—282].  For
example,  siRNA  and  tumor-homing  peptides  (F3)  were  conju-
gated  to  the  PEGylated  QD  core  as  a  scaffold  [278,279]. The
complex  was  efﬁciently  delivered  to  HeLa  cells,  released
from  the  endosomal  compartment,  and  triggered  knockdown
of  EGFP  signal.  This  leads  to  dual  purpose  of  treatment
and  imaging.  In  another  case,  siRNA  was  also  conjugated
to  the  iron  oxide  nanoparticle  [280,282]  for  dual  purpose:
(1)  in  vivo  transfer  of  siRNA  and  (2)  imaging  the  accumula-
tion  of  siRNA  in  tumor  through  magnetic  resonance  imaging
(MRI)  and  near-infrared  in  vivo  optical  imaging  (NIRF)  using
near-infrared  Cy5.5  dye.  Another  report  showed  that  the
conjugation  of  gold  nanoparticle  and  RNA  also  increased  the
availability  of  the  tethered  RNA  splicing  enhancer  [283].
In  2007,  the  pRNA  of  the  phage  phi29  DNA-packaging
motor  was  conjugated  to  the  gold  nanoparticles  via  a
thiol  group  for  single  particle  quantiﬁcation  in  bacterial
virus  assembly  [281].  The  pRNA-gold  nanoparticle  conju-
gates  were  bound  to  procapsid  by  in  vitro  phage  assembly.
The  results  demonstrated  the  feasibility  in  using  RNA-gold
nanoparticle  for  single  molecule  imaging  and  counting  of
biological  machines.
Prospects
RNA  is  a  polymer  by  nature.  Recent  technological  advances
to  make  RNA  chemically  and  enzymatically  stable  [65,66]
and  the  discovery  of  unusual  thermostability  of  some
RNA  motifs,  as  well  as  important  biomedical  applications
[123—126,284]  have  propelled  the  concept  of  RNA  as  a649
olymeric  building  block  [36]  into  a  new  horizon.  The  con-
ern  of  yield  and  production  costs  has  been  and  will  be
ddressed  continually  by  industry  scale  production  and  fer-
entation.  It  is  expected  that  applications  of  RNA  as  a
olymer  and  as  building  blocks  will  appear  more  and  more
n  therapeutics,  detection,  sensing,  nanoelectronic  devices,
nd  other  polymer  industries.  The  anion  nature,  the  thermo-
ynamic  stability,  the  insulating  property,  the  self-assembly
apability  and  other  novel  features  such  as  versatility,
olecular-level  plasticity,  as  well  as  the  potential  semicon-
uctor  behavior  will  make  RNA  unique  for  exploring  new
cientiﬁc  territories.  RNA  has  been  shown  to  be  major  com-
onents  of  cells  and  leading  functionality  of  life,  and  it  is
xpected  that  RNA  will  also  be  the  momentous  material  of
aily  life  in  the  future.
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